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Niemann-Pick type C disease (NPC) is an autosomal recessive lipid 
storage disorder characterized by disrupted sphingolipid and cholesterol 
trafficking that produces cognitive impairment, ataxia and death, often in 
childhood.  Most cases are caused by loss of function mutations in the Npc1 
gene.  We first demonstrated that NPC1 deficient primary human fibroblasts and 
npc1 -/- mice showed increased autophagy, a bulk protein degradation pathway 
that has been implicated in the pathogenesis of several neurodegenerative 
disorders.   Autophagy due to NPC1 deficiency was associated with increased 
expression of Beclin-1, and siRNA knock-down of Beclin-1 decreased the rate of 
protein degradation.  Our data defined a critical role for Beclin-1 in the activation 
of autophagy in NPC. 
Efficient protein degradation by autophagy requires trafficking along 
microtubules.  NPC is characterized by the accumulation of hyperphosphorylated 
and aggregated tau, a microtubule binding protein implicated in the regulation of 
intracellular transport.  To determine whether these changes in tau contribute to 
NPC pathogenesis, we decreased tau expression in cellular and mouse models 
of NPC.  In NPC1 deficient primary human fibroblasts, siRNA knock-down of tau 




earlier and were generated in significantly smaller litters than NPC1 single null 
mutants, demonstrating a genetic interaction between Mapt and Npc1.  Surviving 
double null mutants exhibited an enhanced systemic phenotype that included 
mild facial dysmorphia, kyphosis and an abnormal, toe-walking gait.  Our data 
established that tau modifies the severity of the NPC phenotype through a loss-
of-function mechanism that does not involve neurofibrillary tangle formation or 
tau protein aggregation, and is associated with impaired activation of autophagy. 
 The study of NPC pathogenesis has been limited by the lack of 
mammalian model systems in which Npc1 gene expression can be manipulated 
in a cell type or temporally controlled manner.  To address this problem, in the 
final part of my thesis I used gene targeting to generate a conditional null mutant 
mouse in which Npc1 exon 9 is flanked by loxP sites.  Studies utilizing these 
mice are expected to provide insights into the mechanism of neurodegeneration 




Chapter 1  
Introduction 
 
1.1  Background 
 The sphingolipid-storage diseases are a collection of ~40 genetically 
distinct disorders caused by inherited deficiencies of lysosomal hydrolytic 
activities or lipid transport that result in intracellular accumulations of cholesterol 
and lipids in the endosomal–lysosomal network.  These disorders have an 
aggregate prevalence of approximately 1 in 8000 births worldwide (1). Among 
this group is Niemann–Pick type C disease (NPC, MIM 257220), an autosomal 
recessive, progressive neurovisceral disorder characterized by abnormal 
cholesterol trafficking and by intracellular accumulations of unesterified 
cholesterol and glycosphingolipids in late endosomes and lysosomes (2-8). 
These lipid accumulations cause a multifaceted toxic response in the liver, 
spleen and brain. NPC is caused by loss of function mutations in either NPC1 (9) 
or NPC2 (10); the protein products of these genes mediate proper intracellular 




 NPC patients develop symptoms over a wide range of ages (11), and 
there is no strict correlation between disease-causing mutations and the severity 
of the clinical phenotype (4, 12). While patients may initially exhibit systemic 
findings such as hepatosplenomegaly or obstructive jaundice, all eventually 
develop neurological and/or psychiatric symptoms, the severity of which is 
inversely associated with lifespan (13, 14). Patients presenting with neurological 
symptoms during the first two years of life, classified as the most extreme, 
infantile cases of NPC, demonstrate delayed motor development and hypotonia, 
and typically die within their first 5 years (15). The classical form of NPC, which 
encompasses ~60–70% of cases, presents between the ages of 3 and 15 years. 
Parents of these patients are often the first to notice troublesome signs of the 
disease, such as loss of speech or increasing clumsiness. The disorder 
progresses to cause a constellation of neurological symptoms that may include 
cerebellar ataxia, dysarthria, dysphagia, cataplexy, seizures, dystonia, vertical 
gaze palsy, progressive dementia and death by 8–25 years (11). Adult-onset 
cases of NPC are well documented although much less common, and their 
unusual clinical presentation often initially leads to misdiagnosis. Most adults with 
NPC develop symptoms in their second or third decades of life, although onset 
can occur as late as the mid-sixth decade (16). These adult patients develop 
symptoms similar to the classical form of juvenile NPC and usually die when in 
their late 30s or 40s. At the current time, there are no effective treatments 





1.2  NPC pathology and biochemical defects 
 While heterogeneity characterizes the clinical presentation of NPC, there 
is less pathological heterogeneity at the biochemical level. The vast majority of 
cases show prominent accumulations of unesterified cholesterol, sphingolipids 
and complex gangliosides in late endosomes and lysosomes of most cells types 
of the body (2-4, 11). However, it should be noted that a subset of patients with 
certain mutations demonstrate much less lipid storage (17), and central nervous 
system (CNS) pathology is accompanied by particularly prominent storage of 
sphingolipids and complex gangliosides.  
1.2.1  Histopathology 
 The progression of NPC in the periphery is characterized by an 
enlargement of the liver and spleen that results from the presence of lipid-laden 
macrophages, termed foam cells. Kupffer cells in the liver and splenic 
macrophages, the latter predominantly in the red pulp, exhibit marked 
cytoplasmic vacuolization due to an accumulation of cholesterol, phospholipids 
and glycolipids.  
 Impairment of lipid trafficking also affects the CNS and results in neuron 
loss throughout the brain (18). The occurrence of swollen neuronal cell bodies in 
many brain regions, including cortex, basal ganglia, thalamus, cerebellum and 
brainstem is also characteristic of NPC and reflects lipid accumulation within late 
endosomes and lysosomes. The cell body of these neurons and their axonal 




as membrane-bound polymorphous bodies containing loosely packed lamellae or 
as dense osmiophilic inclusions. Additional neuronal pathology includes the 
formation of ectopic dendrites, swelling of proximal axons to so-called 
meganeurites, and the presence of axonal spheroids – changes indicative of a 
neuroaxonal dystrophy (18). Like several other neurodegenerative diseases, 
NPC is classified as a tauopathy due to the presence of intracellular aggregates 
of the microtubule-binding protein tau, which are biochemically identical to 
aggregates in Alzheimer disease (19). The role of tau pathology in NPC 
pathogenesis is explored in experiments described in Chapter 3. These changes 
in the NPC brain are accompanied by gliosis in grey and white matter, microglial 
activation and cerebral atrophy. 
1.2.2  Biochemistry 
 Lipid-trafficking defects within the NPC brain reflect defects in the pathway 
by which cholesterol and other lipids arrive in neurons and are sorted 
intracellularly. Studies in normal mice have demonstrated that cholesterol 
accumulation in the CNS markedly increases during the first three weeks of life, a 
period of late development and myelination (20, 21). Lipoprotein associated 
cholesterol from the periphery does not cross the blood–brain barrier to enter the 
CNS, even during this early phase of brain development, and therefore de novo 
synthesis is required to meet the needs of both the developing and mature 
nervous system (22-24). Neurons and other CNS cell types obtain the cholesterol 
they require though endogenous synthesis or by uptake of cholesterol, perhaps 




system, possibly by astrocytes (25). Once target cells internalize these particles, 
unesterified cholesterol and companion lipids are trafficked from the endosomal–
lysosomal system to compartments such as the Golgi complex and endoplasmic 
reticulum for processing and to serve as substrates for further reactions (26). 
Derivatives of cholesterol include oxysterols, which signal a decrease in the de 
novo synthesis of cholesterol and therefore provide negative feedback (27, 28).  
 In NPC fibroblasts, lipoprotein cholesterol particles are internalized without 
disruption but become entrapped within trafficking vesicles, particularly late 
endosomes and lysosomes (Fig. 1.1) (29-31). The insufficient efflux of 
cholesterol and lipids out of these structures causes a twofold problem: 
unesterified cholesterol, sphingolipids and complex gangliosides accumulate 
within vesicles in the cytoplasm of the cell, while there is a simultaneous paucity 
of cholesterol and other essential lipids in organelles to which these compounds 
were originally destined. Decreased cholesterol in the endoplasmic reticulum, 
Golgi complex and other internal organelles causes deleterious effects on a 
multitude of processes dependent on proper membrane composition (32). 
Disrupted trafficking also results in a paucity of substrate for further synthetic 
reactions. For example, decreased availability of unesterified cholesterol impairs 
production of oxysterols, which may lead to increased cholesterol synthesis and 





1.3  Genetics of NPC 
 Almost a century has passed since the original reports by Albert Niemann 
and Ludwick Pick described patients with hepatosplenomegaly and rapidly 
progressive brain damage. Since then, biochemical and genetic studies have 
helped define the classification of the Niemann–Pick disease group. Niemann-
Pick types A and B disease (MIM 257200 and 607616), distinct from NPC, are 
caused by loss of function mutations in the acid sphingomyelinase gene, 
encoding an enzyme that metabolizes sphingomyelin to ceramide and 
phosphocholine. Although fibroblasts from NPC patients may show reduced 
sphingomyelinase activity in culture, this reduction is due to an imbalanced lipid 
and cholesterol environment, and removal of cholesterol from the media recovers 
enzymatic activity (34). By contrast, NPC fibroblasts exhibit an accumulation of 
unesterified cholesterol indicative of a defect in cholesterol trafficking. The major 
complementation group for NPC (11) was mapped to the proximal long arm of 
chromosome 18, and mutations in the NPC1 gene were found in ~95% of 
patients with this disease (9). The remaining 5% of NPC patients were 
subsequently found to have loss of function mutations in a separate gene, NPC2 
(10). 
 The NPC1 gene encodes a multipass transmembrane protein, NPC1, 
which is localized to late endosomes and lysosomes (35, 36). The encoded 





Figure 1.1  Lipid trafficking defects in Niemann–Pick type C disease 
(a)  Under normal conditions, lipoprotein cholesterol particles enter the 
endosomal network after binding to cell-surface receptors. Unesterified 
cholesterol and companion lipids are trafficked from the endosomal–
lysosomal system to the Golgi complex, endoplasmic reticulum and other 
intracellular compartments.  (b)  Loss of function of NPC1 or NPC2 inhibits 
the egress of unesterified cholesterol and sphingolipids from late 
endosomes and lysosomes, resulting in their accumulation at these sites 
and a paucity of these lipids at the intracellular compartments to which 
they were destined. Abbreviations: ER, endoplasmic reticulum; NPC, 
Niemann–Pick type C. 
 
regulators of cholesterol metabolism and in Patched [PTCH1], a receptor for the 
secreted signaling protein Hedgehog [SHH] (9, 37). Experimental evidence 
indicates that NPC1 is involved in the efflux of low-density lipoprotein (LDL)-
derived unesterified cholesterol from late endosomes and lysosomes to other 
intracellular compartments (30, 31). Multiple disease-causing mutations within 
the NPC1 coding region have been identified that lead to its loss of function (38). 
The NPC1 protein is conserved within the animal kingdom, and loss of function 




cats (43) and dogs (44) disrupt lipid trafficking. Introduction of the S. cerevisiae 
NPC1 orthologue, ncrp1, into Chinese hamster ovary cells deficient in NPC1 is 
sufficient to reverse lipid trafficking defects associated with NPC1 deficiency, 
demonstrating that this protein is functionally conserved from yeast to mammals 
(39). 
 The NPC2 gene encodes a small, soluble protein that is localized to 
lysosomes, but is also secreted (10, 45). Loss of function mutations in this gene 
result in a disease phenotype that is clinically and biochemically indistinguishable 
from the disease caused by NPC1 mutations. The NPC2 protein binds 
cholesterol, and structural analysis has identified a hydrophobic pocket that 
serves as a putative cholesterol-binding domain (46). Disease-causing mutations 
in NPC2 that affect amino acid residues surrounding this pocket impair 
cholesterol binding (47). Analysis of Npc1–Npc2 double mutant mice 
demonstrates that the disease phenotype is similar to that occurring in Npc1 or 
Npc2 single mutants, providing genetic evidence that the NPC1 and NPC2 
proteins function in the same pathway to regulate intracellular lipid transport (48).  
 
1.4  NPC1-deficient mice  
1.4.1  Phenotype 
 The most commonly used mammalian model of NPC, BALB/cNctr-
Npc1m1N/J mice (Jackson Laboratory #003092), contains a transposon insertion 




express functional NPC1 protein and exhibit a degenerative phenotype that 
begins around 7 weeks (49, 50). The severity of the phenotype progresses with 
age and includes weight loss, tremors, ataxia, and death by 10–12 weeks. The 
liver and spleen contain an abundance of foam cells, reminiscent of the 
histopathological changes seen in humans with this disorder (Fig. 1.2). Recently, 
in vivo antisense knockdown of NPC1 expression only in the liver of normal mice 
has been shown to recapitulate the hepatic pathology associated with NPC, 
generating a novel model to examine liver dysfunction associated with disease 
independent of CNS involvement (51) 
  Global loss of NPC1 expression leads to CNS pathology including 
vacuolated neurons that accumulate glucosylceramide, lactosylceramide, 
complex gangliosides and cholesterol (52-54), abnormally swollen axons, and 
decreased myelination in the cerebral white matter (55). A prominent feature of 
CNS pathology is loss of Purkinje cells, the major neuronal cell type transmitting 
output from the cerebellum (56). These highly specialized neurons are 
responsible for timing and smoothness of movements, and lesions within the 
cerebellum can lead to ataxia. Loss of Purkinje cells is initially apparent in the 
cerebellar vermis by 7 weeks. Progressive Purkinje cell loss proceeds from the 
anterior to posterior vermis, yet largely spares lobules IX and X, even in mice 
with end-stage disease (56). Interestingly, 2-year-old Npc1+/− mice also exhibit 
mild Purkinje cell loss, suggesting that haploinsufficiency for NPC1 may have 




Figure 1.2 Niemann–Pick type C disease pathology 
Foamy macrophages are abundant in the liver and spleen of NPC1-deficient 
mice (examples at arrowheads). In the brain, loss of cerebellar Purkinje 
cells is a prominent pathological feature; these large, pyramidal-shaped 
neurons normally reside at the interface of the molecular layer and granular 
cell layer of the cerebellar folia (examples at arrowheads). These cells die 
in NPC1-deficient mice and are replaced by reactive astrocytes. 
Abbreviation: NPC, Niemann–Pick type C. 
 
1.4.2  Lipid-trafficking defects  
 NPC1-deficient mice have been used to explore how lipid-trafficking 
defects lead to progressive neurodegeneration. Attention has focused on the role 
of glycosphingolipids, including complex gangliosides such as GM2, which 
accumulate in NPC neurons (54); although involved in normal brain 
development, these do not normally accumulate in the adult brain. Their 




formation of ectopic dendrites that branch from swollen axons (18). These 
abnormally long and inappropriately located processes may contribute to 
neuronal dysfunction. Based on this notion, on indications that some 
glycosphingolipids are toxic, and on findings that cholesterol accumulation in the 
NPC brain is ganglioside-dependent (58), glycosphingolipid synthesis has 
emerged as a therapeutic target in NPC and related sphingolipid-storage 
disorders (59-61). 
 Trafficking defects also lead to diminished production of cholesterol 
derivatives including neurosteroids, which normally help mediate brain 
development, growth and differentiation (62). A single injection of the 
neurosteroid allopregnanolone, whose production is significantly decreased in 
NPC mice, is sufficient to promote Purkinje cell survival and delay disease 
phenotype (63). Although initial evidence suggested that this beneficial effect 
was mediated via signaling from the GABAA receptor (class A receptor for γ-
aminobutyric acid), more recent studies indicate that it occurs by activation of the 
pregnane X receptor (PXR) or liver X receptor (LXR) (64). These steroid 
receptors are ligand-activated transcription factors that bind the oxysterols 25-
hydroxycholesterol and 27-hydroxycholesterol (27, 28). Pathways activated by 
the receptors promote efflux of cholesterol from late endosomes and lysosomes, 
and suppress endogenous cholesterol synthesis. Exogenous application of either 
25-hydroxycholesterol or 27-hydroxycholesterol is sufficient to correct sterol 
defects in NPC1-deficient human fibroblasts and to mobilize cholesterol from the 




cholesterol efflux from the NPC mouse brain, slow neurodegeneration and 
prolong life (66), suggesting that activation of these pathways is a promising 
therapeutic strategy. 
1.4.3  Cell-autonomous cell death 
 Defects in lipid trafficking that occur in NPC lead to cell-autonomous 
neuronal death. This was established by an analysis of chimeric mice that 
express functional NPC1 protein in only a subset of cells (67). In this model, 
NPC1-deficient Purkinje cells died, even when neighboring cells harbored normal 
levels of NPC1 protein. Conversely, Purkinje cells with functional NPC1 were 
spared, even in an NPC1-deficient environment. Examination of NPC1-deficient 
Purkinje cells in mutant mice revealed evidence of autophagy, suggesting that 
this pathway is activated in the NPC brain and may play a role in pathogenesis.  
 
1.5  Autophagy 
 Autophagy is a conserved cellular pathway that mediates the turnover of 
damaged or aged macromolecules and organelles. Three types of autophagy 
have been described: microautophagy, chaperone-mediated autophagy and 
macroautophagy (68). For the purposes of this review, we discuss only 
macroautophagy and refer to it simply as ‘autophagy’.  
 At basal levels, autophagy is a house-keeping mechanism for the 




inaccessible to the ubiquitin–proteasome pathway. Regulated degradation is 
governed by activation of autophagy-related genes (ATGs) (69). Autophagy 
begins with the generation of an isolation membrane – a crescent-shaped double 
membrane originating from either smooth ER or another subcellular location that 
has yet to be defined (70). The isolation membrane surrounds cargo targeted for 
degradation (Fig. 1.3). During the engulfment process, two ubiquitin-like 
conjugation reactions are required for progression through autophagy: the 
formation of an ATG12–ATG5–ATG16 complex; and the conjugation of ATG8 
(also known as microtubule-associated protein 1 light chain 3 protein; LC3) to 
phosphatidylethanolamine (71). This latter step is commonly used as a 
biochemical marker for the induction of autophagy (72, 73). Following 
engulfment, mature autophagosomes fuse with lysosomes to enable degradation 
of contents and recycling of their components, a process indicative of flux 
through the autophagic pathway (74).  
 Autophagy can be induced above basal levels by several stimuli, including 
amino acid starvation or cellular stress. This induction is mediated by signaling 
through the mammalian target of rapamycin (mTOR) or through a complex of the 
class III phosphoinositide 3-kinase (PI3K) and Beclin-1 (BECN1) (75). mTOR is a 
negative regulator of autophagy and its chemical inhibition by rapamycin relieves 
this blockade (75, 76). The PI3K–Beclin-1 complex is necessary for the induction 




Figure 1.3  The autophagic pathway 
Autophagy occurs at low, basal levels and can be induced by multiple 
stimuli, including amino acid starvation or mTOR inhibition. It begins with 
the formation of an isolation membrane – a crescent-shaped sequestering 
membrane also termed a phagophore – and the induction of a ubiquitin-like 
conjugation reaction that couples soluble LC3-I with 
phosphatidylethanolamine. Lipidated LC3-II studs the phagophore 
membrane as it engulfs macromolecules, organelles and other cargo 
destined for degradation. Mature autophagosomes fuse with lysosomes to 
form autolysosomes, thereby degrading cargo and enabling components to 
be recycled. Not shown is the fusion of some autophagosomes with 
endosomes to form so-called amphisomes, another vesicle that fuses with 
lysosomes to facilitate cargo degradation. Abbreviations: mTOR, 
mammalian target of rapamycin; LC3, microtubule-associated protein 1 
light chain 3 protein (also known as ATG8).  
 
 
 Autophagy is necessary for normal CNS development and function, and 
has been implicated in the pathogenesis of a diverse array of neurodegenerative 
diseases, including protein-aggregation disorders such as Alzheimer (78), 
Parkinson (79), and Huntington disease (80), as well as the sphingolipid-storage 




inducing autophagy in model systems enhances the clearance of misfolded or 
mutant proteins that are not efficiently degraded by the proteasome. This 
enhancement of protein clearance abrogates disease phenotypes (82), indicating 
that autophagy may have beneficial effects in some disease processes. 
Conversely, genetic deletion in mouse CNS of either of two autophagy related 
genes – Atg5 (83) or Atg7 (84) – leads to neurodegeneration and the 
accumulation of ubiquitinated protein aggregates, demonstrating that basal 
autophagy contributes significantly to protein quality control and cell survival in 
the nervous system.  
 Although the induction of autophagy may alleviate disease in some 
instances, in other situations autophagy can have deleterious effects. In mouse 
embryonic fibroblasts deficient in apoptosis – the classic programmed cell death 
pathway – because they lack the apoptotic effectors BAX and BAK, application of 
death stimuli such as staurosporin or etoposide triggers an apoptosis-
independent cell death pathway (85). Further genetic manipulation of these cells 
through RNA interference knockdown of two autophagy regulators – Atg5 and 
Becn1 – inhibited cell death, demonstrating the occurrence of a death program 
mediated by autophagy. Contributions from autophagic cell death have been 





1.5.1  Autophagy in NPC and other lysosomal storage disorders 
 Induction of autophagy in NPC1-deficient mice was first reported by Ko et 
al., who observed frequent autophagic vacuoles in Purkinje cells of mutant mice 
accompanied by increased accumulation of lipidated LC3 in cerebellar lysates 
(67). Subsequent independent findings (87, 88), including our own work 
presented in Chapter 2, have confirmed autophagy induction in the NPC brain, 
and extended this observation to additional pathologically affected organs, such 
as liver, and to primary human fibroblasts from NPC patients. Flux through the 
autophagic pathway is also increased in NPC1-deficient cells, as confirmed by 
monitoring the degradation of long-lived proteins and by establishing that 
inhibition of lysosomal proteases increases lipidated LC3 levels in mutant cells 
(88); in contrast, inhibition of lysosome function does not alter LC3 levels in 
pathological situations characterized by impaired autophagosome–lysosome 
fusion (74). The induction of autophagy in NPC1 deficiency is not mediated by 
signaling through the AKT–mTOR–S6K1 pathway, but rather by the complex of 
Beclin-1 and class III PI3K (88). Beclin-1 expression is mildly elevated in NPC1-
deficient mouse tissue and human fibroblasts, and Beclin-1 knockdown by small 
interfering RNA decreases long-lived protein degradation (88). Induction of 
autophagy and increased Beclin-1 expression are similarly observed in NPC2-
deficient primary human fibroblasts and in control cells treated with U18666A 
(88-90), a compound known to induce an accumulation of unesterified 
cholesterol. By contrast, Gaucher disease fibroblasts, which traffic sphingolipids 




that autophagy induction is sensitive to alterations in these lipids (88). We 
envision that the complex of Beclin-1 and class III PI3K senses changes due to 
the dysregulation of lipid trafficking in NPC and other disorders and activates 
autophagy.  
 Although NPC1 deficiency is characterized by elevated induction and flux 
through the autophagic pathway, ubiquitinated proteins accumulate in the mutant 
mouse brain. These ubiquitinated proteins can be visualized in cerebellar tissue 
of NPC1-deficient mice by immunohistochemistry (56). Fractionation studies 
indicate that much of this material is in the endosomal–lysosomal compartment 
(87). The paradoxical accumulation of ubiquitinated proteins in the setting of 
increased autophagic degradation suggests that flux though this pathway is not 
sufficient to handle the quantity of proteins targeted for degradation (Fig. 1.4).  
Situations where induction and flux are disproportionate to each other may lead 
to autophagic stress, a possible mediator of neuronal dysfunction and a 




Figure 1.4  Autophagic induction and flux in Niemann–Pick type C and 
other lysosomal storage disorders.  
In healthy cells, macromolecules are efficiently targeted for degradation by 
autophagy in a process characterized by proportionate induction and flux 
through the pathway. This steady-state equilibrium is disrupted in 
Niemann–Pick type C (NPC) disease and other lysosomal storage diseases. 
In NPC, our working model holds that sphingolipid-trafficking defects alter 
membrane lipid composition and induce autophagy through the activity of 
the complex of class III phosphoinositide 3-kinase and Beclin-1. This 
induction can be measured experimentally by an accumulation of LC3-II in 
NCP1- or NPC2-deficient protein lysates. The enhanced induction of 
autophagy occurs coordinately with a more modest increase in autophagic 
flux, resulting in the accumulation of ubiquitinated proteins in tissues from 
NPC patients and animal models. Disproportionate induction and flux 
through the autophagic pathway can lead to cell stress (so-called 
‘autophagic stress’) and may trigger cell death, with dire consequences for 
NPC patients. Abbreviations: LC3, microtubule-associated protein 1 light 






 Impaired flux through the autophagic pathway has also been observed in 
other lysosomal storage disorders, including Pompe disease (92), mucolipidosis 
type IV (93), multiple sulphatase deficiency and mucopolysaccharidosis type IIIA 
(94). Mouse models of many of these disorders exhibit increased lipidated LC3, 
an accumulation of enlarged autophagosomes, and impaired autophagosome–
lysosome fusion resulting in decreased substrate degradation. A similar block of 
autophagosome–lysosome fusion has been documented in a mouse model of 
juvenile neuronal ceroid lipofucinosis, a degenerative disorder caused by 
mutations in a novel, multipass transmembrane protein localized to late 
endosomes and lysosomes (95). These data suggest that impaired flux through 
the autophagic pathway is common to many lysosomal storage diseases, and 
that an imbalance between induction and flux may contribute to the pathology of 
this diverse array of disorders by causing autophagic stress or triggering 
autophagic cell death. 
 
1.6  Clinical implications and outstanding research questions 
 Current therapeutic options for patients with the sphingolipid-storage 
disorders are limited (see Table 1 for a summary of NPC therapeutic strategies). 
For diseases caused by deficiencies of lysosomal hydrolases, ideal therapies 
would replace the deficient enzymes; however, administration presents a 
significant challenge. Intravenous infusion of active enzymes has yielded some 




glycogen-storage disease type II (96). Yet, this approach treats only the systemic 
and not CNS disease manifestations because of limited blood–brain barrier 
permeability. Similarly, bone-marrow transplantation is effective at reducing 
systemic but not neurological symptoms in NPC (97), as is the case for most, but 
not all, sphingolipid-storage disorders (98). An alternative treatment strategy is 
substrate-reduction therapy, which aims to reduce accumulating material in 
endosomes and lysosomes based on the notion that excess substrate 
contributes to pathogenesis. In the case of NPC, reduction of intracellular  
Table 1. NPC therapeutic targets and strategies   
 
Mechanism of action Therapeutic Refs 
Current and former strategies 
Introduction of functional NPC1 or NPC2 Bone marrow transplantation 97 
Substrate reduction therapy     
  Reduction of intracellular cholesterol Cholestyramine, lovastatin and nicotinic acid 99, 100 
  Reduction of glycosphingolipid accumulation Miglustat (N-butyldeoxynojirimycin) 61 
Possible future strategies 
Activation of endogenous pathways that 
promote cholesterol efflux LXR or PXR agonist 
63, 64, 
65, 66 
Chemical modulation of autophagy Rapamycin derivatives or novel autophagy inhibitors 
67, 87, 
88 
Abbreviations: LXR, liver X receptor; NPC, Niemann–Pick type C; PXR, pregnane X 
receptor 
cholesterol by a combination of cholestyramine, lovastatin and nicotinic acid was  
able to lower liver and blood levels of cholesterol, but had little effect on disease  
progression (99, 100). For disorders characterized by neurodegeneration and the 
accumulation of glycosphingolipids in the CNS, small-molecule inhibitors of 
glycosphingolipid synthesis have attracted considerable attention. Iminosugars 
such as miglustat (N-butyl-deoxynojirimycin) are reported to act through this 
mechanism, delay symptom onset and prolong survival in mouse models of NPC 




a small number of NPC patients similarly yielded a mild, encouraging effect after 
one year of treatment (61).   
 Despite these various treatment strategies, only modest clinical 
improvements have been achieved and new therapeutic approaches are needed. 
The recently described relationship between autophagy and NPC may lead to 
novel therapeutic targets. A critical, unanswered question is whether activation of 
this pathway in NPC patients is detrimental and promotes cell death, or is 
compensatory and promotes cell survival. To resolve this issue, autophagy will 
need to be modulated in NPC model systems and effects on disease phenotype 
established. If it is determined that increasing autophagy is beneficial, then 
administration of compounds like rapamycin would be an interesting therapeutic 
strategy. Rapamycin, in the form of Rapamune© (also termed sirolimus), has 
been tested in humans as an immune suppressant for organ-transplant patients 
(102). Alternatively, if autophagy is found to enhance the NPC phenotype, small-
molecule inhibitors of this pathway may provide therapeutic benefit. A search for 
compounds that specifically modulate the activity of the autophagic pathway in 
the CNS will likely yield important reagents for investigational studies of disease 
mechanisms, and may provide lead compounds for the development of new 
treatments. 
 The focus of this thesis is to investigate the pathogenesis of NPC.  In 
Chapter 2, we demonstrate a robust activation of autophagy in mice and human 
fibroblasts deficient in Npc1, which we propose to be a protective response.  In 




fibroblasts disrupts the autophagic pathway and that deletion of endogenous tau 
in mice causes the exacerbation of the NPC phenotype, most likely due to a 
diminished capacity of the autophagic pathway.  Finally, in Chapter 4 we report 
on the generation of a Npc1 conditional mouse model, an important resource 
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Chapter 2  
Autophagy in Niemann-Pick C disease is dependent upon 
Beclin-1 and responsive to lipid trafficking defects 
 
2.1  Abstract 
 Niemann-Pick C disease is an autosomal recessive lipid storage disorder 
characterized by a disruption of sphingolipid and cholesterol trafficking that 
produces cognitive impairment, ataxia and death, often in childhood.  Most cases 
are caused by loss of function mutations in the Npc1 gene, which encodes a 
protein that localizes to late endosomes and functions in lipid sorting and vesicle 
trafficking.  Here we demonstrate that NPC1 deficient primary human fibroblasts, 
like npc1-/- mice, showed increased autophagy as evidenced by elevated LC3-II 
levels, numerous autophagic vacuoles and enhanced degradation of long-lived 
proteins.  Autophagy due to NPC1 deficiency was associated with increased 
expression of Beclin-1 rather than activation of the Akt-mTOR-p70 S6K signaling 
pathway, and siRNA knockdown of Beclin-1 decreased long-lived protein 




treatment with U18666A increased Beclin-1 and LC3-II expression, while 
treatment of NPC1 deficient fibroblasts with the sphingolipid-lowering compound 
NB-DGJ failed to alter the expression of either Beclin-1 or LC3-II.  Primary 
fibroblasts from patients with two other sphingolipid storage diseases 
characterized by sphingolipid trafficking defects, NPC2 deficiency and Sandhoff 
disease, also showed elevated Beclin-1 and LC3-II levels.  In contrast, Gaucher 
disease fibroblasts, which traffic sphingolipids normally, showed wild type levels 
of Beclin-1 and LC3-II.  Our data define a critical role for Beclin-1 in the activation 
of autophagy due to NPC1 deficiency, and reveal an unexpected role for lipid 
trafficking in the regulation of this pathway in patients with several sphingolipid 
storage diseases. 
2.2  Introduction 
 The sphingolipid storage diseases encompass a group of ~40 genetically 
distinct disorders that result from inherited deficiencies of lysosomal hydrolytic 
activities or lipid transport.  These disorders occur with a collective frequency of 1 
in 8000 live births (1), and are often associated with devastating 
neurodegeneration.  Among this group is Niemann-Pick C (NPC) disease, an 
autosomal recessive disorder of lipid trafficking that produces cognitive 
impairment, ataxia and death, most often in childhood (2).  NPC disease is 
characterized by the accumulation of unesterified cholesterol and sphingolipids in 
late endosomes and lysosomes.  95% of NPC disease patients have loss of 
function mutations in the Npc1 gene (3).  The encoded multipass transmembrane 




promote lipid sorting and vesicular trafficking (5-8) through mechanisms that are 
incompletely understood.   
 Mice deficient in NPC1, which reproduce the pathology and lipid trafficking 
defects of NPC disease, arose from a spontaneous mutation in the Npc1 gene 
(npc1 -/- mice) (9).  Similar defects occur in chimeric mice that lack functional 
NPC1 in only some cells (10).  In both cases, NPC1 deficiency leads to the 
activation of macroautophagy (hereafter referred to as autophagy) in the 
cerebellum, a process by which cytoplasmic proteins and organelles are 
sequestered within autophagosomes and are targeted for degradation by 
lysosomes (11).  This regulated and evolutionarily conserved pathway enables 
recycling of limited or damaged cellular constituents to promote cell survival.  
However, in other instances, robust activation of autophagy leads to cell death. 
  Here we have used npc1 -/- mice and primary human fibroblasts deficient 
in NPC1 to explore the mechanism by which autophagy is induced in NPC 
disease.  Our data demonstrate that enhanced basal autophagy in NPC1 
deficiency is mediated by increased expression of Beclin-1 rather than by 
activation of the Akt-mTOR-p70 S6K pathway.  We further demonstrate that lipid 
trafficking defects caused by pharmacological treatment or by human disease 
gene mutations occurring in other sphingolipid storage diseases also up-regulate 
Beclin-1 and result in increased autophagy.  Our findings establish Beclin-1 as a 





2.3  Materials and Methods 
2.3.1  Materials 
Mouse samples were from age and sex matched BALB/cNctr-Npc1m1N/J 
(Jackson Laboratories stock number 003092) and wild type littermates.  Human 
fibroblasts from age and sex matched donors were from Coriell Cell Repositories 
(control cells GM00038C, NPC1 deficient GM03123A, NPC2 deficient GM17910, 
Gaucher disease GM10915, Sandhoff disease GM11707).  Filipin, rapamycin, 
E64d, pepstatin A, anti-FLAG M2 monoclonal antibody, G418 and U18666A were 
from Sigma.  NB-DGJ was from Toronto Research Chemicals.  β-tubulin and 
Beclin-1 (BECN1) antibodies were from Santa Cruz Biotechnology.  phospho-Akt 
(Ser473), total Akt, phospho-p70 S6K (Thr412) and total p70 S6K antibodies 
were from Upstate.  phospho-mTOR (Ser2448) and total mTOR antibodies were 
from Cell Signaling. GAPDH antibody was from Abcam.  anti-LC3 antibody was a 
gift from Dr. Tamotsu Yoshimori.  Secondary HRP conjugated goat anti-rabbit 
and goat anti-mouse antibodies were from BioRad. 
2.3.2  Cell culture 
Fibroblasts were maintained at 37°C, 5% CO2 in MEM with Earle’s salts and non-
essential amino acids (Gibco), supplemented with 15% FBS (Atlanta Biologicals) 
and 10 µg/mL penicillin, 10 µg/mL streptomycin and 2 mM glutamine (referred to 




2.3.3  Western blot analysis 
Cells were harvested, washed with PBS and lysed in RIPA buffer containing 
cOmplete Protease Inhibitor Cocktail (Roche Diagnostics) and 0.1% β-
mercaptoethanol.  Liver and cerebellar samples were homogenized in this same 
buffer using a motor homogenizer.  Lysates were precleared by centrifugation at 
15,000 g for 10 min at 4oC. Samples were electrophoresed through either a 10% 
SDS-polyacrylamide gel or a 4-20% tris-glycine gradient gel (Cambrex) then 
transferred to Immunobilon-P (Millipore) or nitrocellulose membranes (BioRad) 
using a semidry transfer apparatus.  Immunoreactive proteins were detected by 
chemiluminescence (PerkinElmer).  Western blots depicted show representative 
results from one of three experiments. 
2.3.4  Electron microscopy 
Cells were fixed in suspension with 4% glutaraldehyde in 0.1 M calcodylate 
buffer, pH 7.3, overnight at 40C, and then post-fixed for 1 hour at room 
temperature in 2% osmium tetraoxide in 0.1 M cacodylate.  After dehydration 
with graded ethanols and propylene oxide, cells were embedded in Epon.  Thin 
sections were stained with uranyl acetate and lead citrate and observed on a 
Philips 400T transmission electron microscope. 
2.3.5  Monodansylcadaverine staining 
Cells were seeded in 6 well plates at equal density in complete MEM medium for 




were incubated with 0.05 mM MDC in PBS for 10 minutes, then harvested, 
washed with PBS and collected in 10 mM Tris-HCl, pH 8.0, with 0.1% Triton X-
100.  Fluorescence of incorporated intracellular MDC (excitation wavelength 390 
nm, emission filter 527 nm) was measured by an Ascent Fluroskan microplate 
reader.  To normalize for cell number, a final concentration of 0.2 µM ethidium 
bromide was added to the suspension and DNA fluorescence was measured 
(excitation wavelength 544 nm, emission filter 590 nm). 
2.3.6  pCMV-mNPC1-3xFLAG expression construct and stable line 
The mouse NPC1 cDNA was amplified from pBS-KS(+)mNPC1 (gift from Dr. 
William Pavan) and an Asp718 site was added at the 3’end.  An intermediate 
construct was generated by ligation of a 1 kB Asp718/EcoR1 fragment from the 
mNPC1 PCR product to the p3XFLAG-CMV-14 vector (Sigma) after 
Asp718/EcoR1 digestion.  The final expression vector was generated by ligation 
of a 3 kB EcoR1 fragment from the pBS-KS (+) mNPC1 plasmid to the EcoR1-
linearized intermediate construct.  All amplified regions and cloning sites were 
verified by restriction digestion and sequencing. 
The plasmid was electroporated into NPC1 deficient human fibroblasts with the 
Amaxa kit for normal human dermal fibroblasts (adult) using program U-23 on the 
Amaxa Nucleofector.  Cells were plated in complete MEM medium for 2 days, 
and then selected with 1 mg/mL G418 in complete MEM medium for 1 week.  
Cells were allowed to recover from G418 selection for 3 days and were 




2.3.7  Measurement of long-lived protein degradation 
Degradation of long-lived proteins was determined using the published method 
(18) with minor modifications.  Cells were seeded in 12 well plates in complete 
MEM for 24 hours and allowed to grow to 70-80% confluency.  After washing with 
HBSS, cells were labeled with 2 µCi/mL 3H leucine (Amersham) in complete 
MEM medium.  After 48 hours of labeling, cells were washed with HBSS and 
incubated with complete MEM supplemented with 2.8 mM leucine.  Aliquots of 
medium were collected at the indicated times, 20% TCA was added and samples 
were stored at 4°C.  Upon acquisition of all samples, BSA (final concentration 3 
mg/mL) was added, samples were incubated at 4°C for 1 hour and then 
centrifuged at 15,000 g for 5 minutes at 4°C.  Supernatants were collected, the 
pellets were washed twice with cold 20% TCA, then all supernatants were pooled 
and the total radioactivity was measured by scintillation counting.  After the last 
time point was collected, cells were washed with PBS and incubated for one hour 
at 37°C in 0.1 N NaOH/0.1% Na deoxycolate.  An aliquot of the solubilized cells 
was used to determine total protein concentration (BioRad).  Relative proteolysis 
was determined by normalizing TCA soluble radioactivity in the medium to 
protein concentration from the solubilized cells. 
2.3.8  siRNA knockdown of Beclin-1 
Fibroblasts growing in complete MEM media were collected using the Reagent 
Pack subculture reagent kit (BioWhitaker), resuspended in Nucleofector solution 




TARGETplus SMART pool human BECN1 (NM_003766) siRNA (L-010552-00-
0005) or siCONTROLplus non-targeting pool (D-001810-10-05) (Dharmacon).  
The suspension was electroporated using program U-23 on the Amaxa 
Nucleofector.  Cells were plated in 12 well dishes and 4 hours later were used to 
measure protein degradation.  Alternatively, cell lysates were collected 24 after 
electroporation for western blot.  
2.3.9  Filipin Staining  
Cells were seeded in chamber slides and incubated in complete MEM medium 
for 24 hours.  After washing with PBS, cells were fixed in 3% paraformaldehyde 
for 1 hour at room temperature, washed with PBS and incubated with 1.5 mg/mL 
glycine in PBS for 10 minutes at room temperature.  Cells were then stained for 2 
hours with 0.05 mg/mL filipin in PBS supplemented with 10% FBS at room 
temperature.  Staining was visualized by fluorescence microscopy using the UV 
filter set on a Zeiss Axioplan 2 imaging system 
 
2.4  Results 
2.4.1  NPC1 deficiency increases basal autophagy. 
 We first sought to determine whether elevated levels of autophagy occur 
specifically in the central nervous system of NPC1 deficient (npc1-/-) mice or also 
occur in other organs that exhibit pathology.  To accomplish this, we used the 




This protein is modified from its LC3-I cytosolic form to a more rapidly migrating, 
lipid conjugated LC3-II form associated with autophagosome membranes when 
autophagy is induced (12, 13).  Cerebellar and liver lysates from 6-week old 
npc1-/- mice had elevated levels of LC3-II compared to wild type littermates (Fig. 
2.1, A) demonstrating that NPC1 deficiency increased autophagy in both organs.  
Similarly, primary human fibroblasts deficient in NPC1 expressed higher total 
LC3 and LC3-II levels than control fibroblasts (Fig. 2.1, B).  This difference was 
observed in untreated cells and following starvation or rapamycin treatment, 
indicating that basal levels of autophagy were increased by NPC1 deficiency and 
that pathways leading to its further activation were intact in mutant cells.  
 High levels of basal autophagy in NPC1 deficient fibroblasts were 
confirmed by transmission electron microscopy (Fig. 2.1, C).  This analysis 
demonstrated frequent autophagic vacuoles containing rough ER and other 
cytoplasmic contents in mutant but not in wild type fibroblasts.  Similarly, staining 
with monodansylcadaverine (MDC), a dye that preferentially incorporates into 
autophagic vacuoles (14, 15) , was significantly higher in NPC1 deficient than 
control fibroblasts (Fig. 2.1, D).  To determine whether exogenous NPC1 could 
decrease autophagy in mutant fibroblasts, we stably expressed NPC1 protein in 
null cells.  We observed decreased total LC3 and LC3-II levels in pooled NPC1 
transfected cells (Fig. 2.1, E) demonstrating that exogenous NPC1 diminished 





Figure 2.1  Increased autophagy in NPC1 deficient mice and human 
fibroblasts. 
(A)  Cerebellar (lane 1, 2) and liver (lane 3, 4) lysates from 6 week old wild 
type (lane 1, 3) and npc1 -/- (lane 2, 4) mice were examined by western blot 
for expression of LC3 (top) and β-tubulin (bottom).  (B)  Lysates from 
control (lanes 1-3) and NPC1 deficient (lanes 4-6) human fibroblasts were 
collected from untreated cells (lanes 1, 4), following 2 hr starvation (lanes 
2, 5) or 24 hr rapamycin (1 µM) treatment (lanes 3, 6).  LC3 (top) and β-
tubulin (bottom) were visualized by western blot.  (C)  Electron 
micrographs of control human fibroblast (left panel) with infrequent 
cytoplasmic vacuoles, and NPC1 deficient fibroblasts (middle and right 
panels) with frequent vacuoles.  Middle panel shows low and high (inset) 
magnification images of membrane bound vacuoles with cytoplasmic 
contents consistent with autophagosomes or autolysosomes.  Right panel 
shows autophagic vacuoles and mutilamellar bodies.  Scale bars in lower 
right.  N is nucleus.  (D)  MDC staining of control and NPC1 deficient human 
fibroblasts normalized to cell number (mean +/- SD).  P < 0.02 by unpaired 
Student’s t test. (e) Lysates from NPC1 deficient human fibroblasts stably 
expressing FLAG-tagged NPC1 protein (lane 2) or empty vector (lane 1) 
were examined by western blot for expression of NPC1 (anti-FLAG, top), 





 We next sought to determine whether the autophagic pathway was intact 
in NPC1 deficient cells.  LC3-II is degraded following fusion of autophagosomes 
with lysosomes (16).  Failure to complete this step, as seen in other lysosomal 
storage diseases (17), increases LC3-II levels yet renders them resistant to 
further elevation upon inhibition of lysosomal proteases (16).  Treatment of both 
wild type and NPC1 deficient fibroblasts with lysosomal protease inhibitors E64d 
and pepstatin A similarly increased LC3-II levels, consistent with the notion that 
fusion of autophagosomes to lysosomes was intact in mutant cells (Fig. 2.2, A).  
This conclusion was supported by the additive effect of concurrent induction of 






Figure 2.2 The autophagic pathway is intact in NPC1 deficiency 
(A)  Lysates from control (lanes 1-4) and NPC1 deficient (lanes 5-8) human 
fibroblasts were collected from untreated cells (lanes 1, 5) or following 24 
hr treatment with rapamycin (1 µM) or E64d (10 µg/mL) plus pepstatin A (10 
µg/mL), as indicated.  Expression of LC3 (top) and β-tubulin (bottom) were 
determined by western blot.  (B)  Degradation of long-lived proteins in 
control (solid line) and NPC1 deficient (dashed line) human fibroblasts.  
Data (mean +/- SEM) are reported relative to control cells at 24 hr.  P = 
0.0006 at 6 hr, 0.01 at 12 hr and 0.005 at 24 hr by unpaired Student’s t test.  
 
 As an independent confirmation that the autophagic pathway was intact in 
NPC1 deficient cells, we measured the degradation of long-lived proteins (18) .  
This assay provides a functional readout since autophagy is the major pathway 
through which many of these proteins are degraded (19, 20) .   Wild type and 
NPC1 deficient fibroblasts were labeled with 3H-leucine for 48 hrs, then washed 
and re-fed, and trichloroacetic acid (TCA) soluble radioactive counts were 




levels of proteolysis were detected by NPC1 deficient fibroblasts at all points, 
demonstrating increased protein turnover in cells that also exhibited enhanced 
autophagy. 
2.4.2  Beclin-1 mediates increased levels of autophagy in NPC1 deficiency. 
 The induction of autophagy is achieved through either the 
dephosphorylation of mTOR or the activation of the Beclin-1 pathway (11) .  To 
determine which of these was preferentially activated in NPC1 deficiency, protein 
lysates from mutant mice and fibroblasts were examined by western blot (Fig. 
2.3).  Beclin-1, an evolutionarily conserved protein that is part of the Class III 
PI3K complex that participates in autophagosome formation (21) , was 
expressed at mildly increased levels in both cerebellum and liver of npc1 -/- mice 
compared to wild type littermates (Fig. 2.3, A).  Increased Beclin-1 expression 
was also observed in NPC1 deficient fibroblasts (Fig. 2.3, B) demonstrating that 
up-regulation of Beclin-1 occurred in response to NPC1 deficiency in mice and 
cells. 
 In contrast, our analyses did not reveal activation of the mTOR pathway 
as a consequence of NPC1 deficiency.  No alteration in the phosphorylation of 
mTOR, its regulator Akt or its target p70 S6K was detected in npc1 -/- mice or 
NPC1 deficient fibroblasts (Fig. 2.3, C and D).  We did, however, observe 
stimulation of the mTOR pathway in NPC1 deficient fibroblasts as evidenced by 
starvation-induced Akt dephosphorylation or rapamycin-induced p70 S6K 




Figure 2.3  NPC1 deficiency causes Beclin-1 up-regulation but not mTOR 
activation. 
(A)  Cerebellar (lane 1, 2) and liver (lane 3, 4) lysates from wild type (lane 1, 
3) and npc1 -/- (lane 2, 4) mice were examined by western blot for 
expression of Beclin-1 (top) and GAPDH (bottom).  (B)  Lysates from 
untreated control (lane 1) and NPC1 deficient (lanes 2) human fibroblasts 
were analyzed by western blot for expression of Beclin-1 (top) and β-tubulin 
(bottom).  (C)  Cerebellar (C) and liver (L) lysates from wild type (lanes 1, 2) 
and npc1 -/- (lanes 3, 4) mice were probed for phosphorylated-Akt, total 
Akt, phosphorylated-mTOR and total mTOR and visualized by western blot.  
(D)  Lysates from control (lanes 1, 2) and NPC1 deficient (lanes 3, 4) 
fibroblasts were collected from untreated cells (lanes 1, 3) or from cells 
following 2 hr starvation (lanes 2, 4; Akt rows) or 24 hr rapamycin (1 µM) 
treatment (lanes 2, 4; p70 S6K rows).  Expression of phosphorylated-Akt 
(upper band = specific), total Akt, phosphorylated-mTOR, total mTOR, 





These data demonstrated that NPC1 deficiency did not activate the Akt-mTOR-
p70 S6K signaling pathway in cell culture or in mice.  
 To determine the extent to which Beclin-1 up-regulation mediated 
enhanced basal autophagy in NPC1 deficient fibroblasts, we used pooled, 
targeted siRNAs to specifically knockdown Beclin-1 expression (Fig. 2.4, A).  
Treatment with Beclin-1 siRNAs significantly decreased degradation of long-lived 
proteins in NPC1 deficient but not wild type fibroblasts (Fig. 4, B).  We conclude 
that activation of Beclin-1 and not the mTOR pathway mediated increased basal 
autophagy in NPC1 deficiency.   
 
Figure 2.4  siRNA knockdown of Beclin-1 is sufficient to decrease basal 
autophagy in NPC1 deficient fibroblasts. 
(A)  Lysates from mock (lane 1), non-targeted siRNA (lane 2) and Beclin-1 
siRNA (lane 3) transfected NPC1 deficient fibroblasts were analyzed by 
western blot for expression of Beclin-1 (top) and GAPDH (bottom).  (B)  
Degradation of long-lived proteins in control and NPC1 deficient human 
fibroblasts following transfection with non-targeted siRNA (black bars) or 
Beclin-1 siRNA (white bars).  Data (mean +/- SEM) are reported relative non-
targeted siRNA transfected cells at 24 hr.  Relative proteolysis is 
significantly decreased in NPC1 deficient cells (P = 0.018 by unpaired 




2.4.3  Defects in lipid trafficking lead to up-regulation of Beclin-1.  
 NPC disease is characterized by the accumulation of both unesterified 
cholesterol and glycosphingolipids in late endosomes and lysosomes.  This 
trafficking defect creates a functional deficit of cholesterol in other intracellular 
compartments (22-24).  It was recently demonstrated that autophagy is 
responsive to intracellular cholesterol levels (25, 26).  We therefore treated 
control fibroblasts with U18666A, a compound known to induce an accumulation 
of unesterified cholesterol similar to that occurring in NPC1 deficiency (27) (Fig. 
2.5, A).  U18666A treatment of control fibroblasts resulted in increased 
expression of both LC3-II and Beclin-1 (Fig. 2.5, B), suggesting that cholesterol 
trafficking defects were sufficient to activate autophagy and increase Beclin-1 
expression.  
 To evaluate the effect of glycosphingolipids on the induction of autophagy, 
NPC1 deficient cells were treated with the imino sugar N-butyl-
deoxygalactonojirimycin (NB-DGJ).  Although this compound decreases 
glycosphingolipid levels in NPC1 deficient cells (28), NB-DGJ treatment did not 
alter LC3-II or Beclin-1 expression (Fig. 2.5, C).  These findings support the 
notion that elevated basal autophagy in NPC1 deficient cells was primarily a 





Figure 2.5  Unesterified cholesterol accumulation increases Beclin-1 and 
LC3-II expression. 
(A)  Filipin staining of unesterified cholesterol in untreated control and 
NPC1 deficient fibroblasts, and control fibroblasts after 24 hr treatment 
with U18666A (1 µg/ml).  (B)  Lysates from untreated (lane 1, 2) and 
U18666A-treated (1 µg/ml, 24 hr) control fibroblasts were analyzed for 
expression of LC3 (top), Beclin-1 (middle) and β-tubulin (bottom) by 
western blot.  (C)  Lysates from untreated NPC1 deficient fibroblasts (lane 
1) or following treatment with NB-DGJ (50 µM) for 1, 3 or 5 days (lanes 2-4) 






 To further explore the relationship between lipid trafficking defects, Beclin-
1 expression and autophagy, we used a panel of primary human fibroblasts 
derived from patients with several sphingolipid storage diseases.  NPC2 
deficiency, which results in a clinical and biochemical phenocopy of NPC1 
deficiency and causes ~5% of NPC disease (29), resulted in elevated basal 
levels of Beclin-1 and LC3-II (Fig. 2.6, A and B).  Sandhoff disease fibroblasts, 
which traffic sphingolipids abnormally (30-32), similarly exhibited elevated basal 
Beclin-1 and starvation-induced LC3-II levels (Fig. 2.6, A and B).  In contrast, 
Gaucher disease fibroblasts, which lack sphingolipid trafficking defects (30-32), 
showed wild type basal levels of Beclin-1 and starvation-induced LC3-II 
expression (Fig. 2.6, A and B).  Taken together, these analyses revealed an 
unexpected contribution of lipid trafficking defects to the regulation of autophagy 






Figure 2.6  Other sphingolipidoses, which are characterized by lipid 
trafficking defects, display increased Beclin-1 expression. 
(A)  Lysates from untreated control fibroblasts (lane 1), or from patients 
with NPC2 deficiency (lane 2), Gaucher disease (lane 3) and Sandhoff 
disease (lane 4) were analyzed for expression of Beclin-1 (top) and β-
tubulin (bottom) by western blot.  (B)  Lysates were collected from 
untreated control (lane 1), NPC1 deficient (lane 2) and NPC2 deficient (lane 
3) fibroblasts, and from 2 hr serum starved control (lane 4), Gaucher 
disease (lane 5), NPC1 deficient (lane 6) and Sandhoff disease (lane 7) 
fibroblasts.  Expression of LC3 (top) and β-tubulin (bottom) were 
determined by western blot. 
 
2.5  Discussion 
 The studies reported here help define the relationship between defects in 
lipid trafficking, autophagy and disease.  Cholesterol and sphingolipid 
accumulations in late endosomes and lysosomes of NPC1 deficient cells are 
biochemical hallmarks of NPC disease.  This disruption of lipid trafficking is 




demonstrating increased autophagy following depletion of intracellular 
cholesterol (25, 26), we explored the mechanism of autophagy up-regulation  
using primary human fibroblasts and mice deficient in NPC1.  Our data establish 
that NPC1 deficiency leads to increased basal autophagy as evidenced by 
elevated LC3-II levels, frequent autophagic vacuoles, increased MDC staining 
and enhanced degradation of long-lived proteins.  This induction of autophagy is 
associated with increased expression of Beclin-1 rather than activation of the 
Akt-mTOR-p70 S6K pathway.  Down-regulation of Beclin-1 by siRNA decreased 
the degradation of long-lived proteins in NPC1 deficient but not wild type 
fibroblasts, demonstrating a critical role for Beclin-1 in the regulation of basal 
autophagy rates. 
 Beclin-1 is the mammalian ortholog of yeast Atg6, and is a cytosolic 
protein that is part of the Class III PI3K machinery that participates in 
autophagosome formation (21).  In addition to its role as a regulator of 
autophagy, Beclin-1 interacts with the anti-apoptotic protein Bcl-2, providing an 
intriguing link between pathways controlling autophagy and cell death (33) .  The 
interaction of Beclin-1 with Bcl-2 inhibits autophagy, while Beclin-1 expression in 
the absence of Bcl-2 binding potently induces autophagy (33).  Thus, induction of 
Beclin-1 expression in Niemann-Pick C disease may simultaneously affect 
autophagy and cell survival.  Interestingly, pharmacologic disruption of 
cholesterol trafficking, which we show induces autophagy, also triggers apoptosis 




Pick C neuropathology has not yet been demonstrated (36) and autophagy may 
influence cell viability through other mechanisms.  
 Beclin-1 expression was increased by pharmacological treatments that 
cause an accumulation of unesterified cholesterol and by human disease gene 
mutations that disrupt lipid trafficking.  Treatment of wild type fibroblasts with 
U18666A and examination of primary cells from patients with NPC2 deficiency 
and Sandhoff disease revealed increased Beclin-1 levels, consistent with the 
notion that expression of this autophagy regulator is elevated in cells with 
defective cholesterol or sphingolipid transport.  In contrast, Gaucher disease 
fibroblasts both traffic sphingolipids normally (30-32) and express wild type levels 
of Beclin-1 and LC3-II.   Although Beclin-1 levels were elevated in Sandhoff 
disease fibroblasts, basal LC3-II levels were not increased (data not shown) and 
expression beyond wild type levels was detected only after serum starvation.  We 
conclude that Beclin-1 up-regulation is necessary but not sufficient to increase 
basal autophagy.  The enhanced response of Sandhoff disease fibroblasts to 
serum starvation suggests that elevated Beclin-1 levels prime cells for autophagy 
induction in response to additional signals.  
 Our observations indicate that the Beclin-1/Class III PI3K complex is a 
critical regulator of autophagy in several sphingolipid storage diseases.  
Activation of this pathway may promote cell survival by generating building 
blocks that are otherwise limiting, as is well characterized during periods of 
amino acid deprivation (11), or by facilitating the removal of damaged organelles 




deficient cells acts in this manner to promote cell survival.  This notion is 
consistent with recently characterized Atg5 and Atg7 null mice in which 
suppression of autophagy leads to neurodegeneration (37-39).  Autophagy has 
also been implicated in non-apoptotic cell death, and its robust activation in 
starved or rapamycin treated cells may lead to cellular demise.  This type of 
cytotoxicity has been demonstrated in bax/bak deficient cells that undergo 
caspase-independent, autophagic cell death following etopiside treatment (40) .  
Our data suggest that modulating activity of the Beclin-1/Class III PI3K complex 
and altering rates of autophagy may be a promising therapeutic approach for 
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Chapter 3  
Tau deletion exacerbates the phenotype of Niemann-Pick type C 
disease mice and implicates autophagy in disease pathogenesis 
 
3.1  Abstract 
 Hyperphosphorylation and aggregation of the microtubule binding protein 
tau characterizes a diverse array of neurodegenerative disorders.  Most of these 
lack mutations in the encoding MAPT gene, and the role of tau pathology in 
pathogenesis remains controversial.  Among these disorders is Niemann-Pick 
type C disease (NPC), a lysosomal storage disease characterized by progressive 
neurodegeneration and premature death, most often caused by an inherited 
deficiency in the intracellular lipid trafficking protein NPC1.  Neurofibrillary tangles 
appear in the brains of NPC patients and hyperphosphorylated tau accumulates 
in Npc1 -/- mouse brains.  To determine the extent to which tau pathology affects 
NPC pathogenesis, we generated Npc1 -/- mice deficient in tau.  Here we show 
that NPC1/tau double null mutants are generated in markedly smaller litters and 
die significantly earlier than single null mutants, demonstrating a genetic 
interaction between Mapt and Npc1 that affects fertility and lifespan.  Surviving 
double null mutants exhibit an enhanced systemic phenotype including mild facial 
dysmorphia, kyphosis, penile prolapse and an abnormal, toe-walking gait. 




reveals an accumulation of LC3-positive autophagic vacuoles.  Autophagy, the 
conserved pathway of bulk protein degradation, is dependent upon movement 
along microtubules and is up-regulated in NPC.  We show that siRNA knockdown 
of MAPT in NPC1-deficient fibroblasts reduced LC3-II levels and decreased long-
lived protein degradation, a measure of flux through the autophagic pathway.  
Our data establish that tau modifies the severity of the NPC phenotype through a 
loss-of-function mechanism that is independent of tau protein aggregation, and 
suggest that impaired autophagy contributes this effect.  
3.2  Introduction 
Niemann-Pick type C disease (NPC) is an autosomal recessive 
sphingolipid storage disorder characterized by severe, progressive 
neurodegeneration, hepatosplenomegaly and premature death (1).  Most cases 
are caused by loss-of-function mutations in NPC1 (2), which encodes a multipass 
transmembrane protein that functions in late endosomes and lysosomes to 
facilitate intracellular lipid trafficking, possibly by acting as a cholesterol efflux 
pump (3-6).  In the absence of functional NPC1, glycosphingolipids, complex 
gangliosides and unesterified cholesterol accumulate within cells, demonstrating 
a critical role for this protein in lipid sorting.  
Children with NPC are among the youngest patients to develop 
neurofibrillary pathology, similar to that which occurs in Alzheimer disease and 
the frontotemporal dementias (7, 8).  In these disorders, the brain accumulates 




tau protein is encoded by six alternatively spliced transcripts derived from the 
MAPT gene and directly binds microtubules through three or four C-terminal 
tubulin-binding domains (10, 11).  Experimental evidence suggests that a primary 
function of tau is to stabilize polymerized microtubules (12).  
Hyperphosphorylation dissociates tau from microtubules and allows for its self-
aggregation into paired helical filaments (PHFs).  These PHFs have the ability to 
form larger aggregates termed neurofibrillary tangles, a pathologic hallmark of 
many tauopathies, and these or other, soluble tau species can act through a toxic 
gain-of-function mechanism to impair neuronal survival (9).  The diminished 
association of hyperphosphorylated tau with microtubules also leads to a loss-of-
function that is presumably detrimental to neuronal health due to its impact on 
axonal transport processes (13), however the significance of this mechanism in 
disease has been uncertain.  Emerging data additionally suggest novel roles for 
tau in the regulation of anterograde and retrograde trafficking that are separate 
from microtubule stabilization (14, 15).  Remarkably, mutant mice which lack 
endogenous tau (Mapt -/- mice) exhibit no overt phenotype (13), likely due to 
functional redundancy with other microtubule associated proteins.  Clearly, our 
current understanding of the normal function of tau and its role in 
neurodegenerative diseases is incomplete. 
In Npc1 -/- mice, tau is hyperphosphorylated at multiple sites in a similar 
manner to human tauopathies, although neurofibrillary tangles do not form (16, 
17).  Cyclin-dependent kinase inhibitors reduce tau phosphorylation and 




disease pathogenesis.  However, it remains unknown whether this therapeutic 
effect is mediated by increased availability of functional tau protein, through 
decreased formation of toxic tau species, or through actions on a different 
substrate.  To define the role of tau in NPC pathogenesis, we generated NPC1 
null mice that lack endogenous tau.  Here we show that tau deletion exacerbates 
the phenotype of NPC mice, resulting in smaller litter size, an enhanced systemic 
phenotype and early death.  Furthermore, we demonstrate that tau knockdown in 
a cellular model of NPC diminishes macroautophagy (hereafter referred to as 
autophagy), a highly conserved pathway by which cytoplasmic proteins and 
damaged organelles are sequestered within autophagic vacuoles and targeted to 
lysosomes for degradation (19).  Prior work has implicated this pathway in the 
pathogenesis of several neurodegenerative disorders (20-23), including NPC 
(24-26).  Functional autophagy is dependent upon trafficking along microtubules 
(27, 28), and its impairment is sufficient to cause neurodegeneration in mice (29, 
30).  Our data establish that tau deletion exacerbates the NPC phenotype in 
mice, and suggest impaired autophagy contributes to this effect.  
3.3  Materials and Methods 
3.3.1  Materials 
Human fibroblasts from age- and sex-matched donors were from Coriell Cell 
Repositories (control cells, GM00038C and NPC1-deficient, GM03123A).  All 
mouse samples were from age- and sex-matched BALB/cNctr-Npc1m1N/J 




backcrossed onto C57BL/6J for five generations.  Anti-LC3 antibody was from 
Novus Biologicals.  GAPDH antibody was from Abcam.  Hsp90 antibody was 
from Santa Cruz.  Anti-hsp40 and an antibody specific for the stress inducible 
form of hsp70 (SPA-812) were from Stressgen.  Anti-20S proteasome was from 
Calbiochem.  The p62 (C-terminal) antibody was from American Research 
Products.  HRP conjugated secondary antibodies were from Biorad (goat anti-
rabbit and goat anti-mouse) and Zymed (rabbit anti-guinea pig).  MG132 was 
from Sigma. 
3.3.2  Cell culture 
Fibroblasts were maintained at 37°C, 5% CO2 in MEM with Earle’s salts and non-
essential amino acids (Gibco), supplemented with 15% FBS (Atlanta Biologicals) 
and 10 µg/ml penicillin, 10 µg/ml streptomycin and 2 mM glutamine (referred to 
as complete MEM medium). 
3.3.3  siRNA knockdown of MAPT 
Fibroblasts growing in complete MEM media were collected using the Reagent 
Pack subculture kit (BioWhitaker), resuspended in Nucleofector solution (human 
dermal fibroblast Nucleofector kit, Amaxa) and mixed with 1.5 µg ON-
TARGETplus SMART pool human MAPT (NM_016841) siRNA (L-012488-00-
0005) or siCONTROLplus-plus non targeting pool (D-001810-10-05) 
(Dharmacon).  The suspension was electroporated using the program U-23 on 
the Amaxa Nucleofector.  Cells were plated in 6-well dishes and total RNA was 




Alternatively, cell lysates were collected 72 h after electroporation for western 
blotting. 
3.3.4  Gene expression analysis 
Total RNA isolated from cells with Trizol (Invitrogen) served as a template for 
cDNA synthesis using the High Capacity cDNA Archive Kit from Applied 
Biosystems.  Gene-specific primers and probes labeled with a fluorescent 
reporter dye and quencher were purchased from Applied Biosystems.  TaqMan 
assays were performed using 5 ng aliquots of cDNA.  Replicate tubes were 
analyzed for the expression of 18S ribosomal RNA (rRNA) using a VIC-labeled 
probe.  Threshold cycle (Ct) values were determined by an ABI Prism 7900HT 
Sequence Detection System and relative expression levels were calculated using 
the standard curve method of analysis. 
3.3.5  Measurement of long-lived protein degradation 
Degradation of long-lived proteins was determined as previously described (25) 
with minor modifications.  Cells were pooled after electroporation and then 
seeded in 6-well plates in complete MEM for 4 h. The cells were then washed 
with HBSS and labeled with 2 µCi/ml 3H-leucine (Amersham) in complete MEM.  
After 48 h of labeling, cells were washed with HBSS and incubated in complete 
MEM supplemented with 2.8 mM leucine.  Aliquots of medium were collected at 
the indicated times and added to 20% TCA, and then BSA was added to a final 
concentration of 3 mg/ml.  All samples were stored at 4°C for at least 1 hour, and 




pellets were washed twice with cold 20% TCA, then all supernatants for each 
sample were pooled and the total radioactivity was measured by scintillation 
counting.  Pellets were dissolved in cell lysis buffer (0.1 N NaOH/0.1% Na 
deoxycolate) and radioactivity was measured by scintillation counting.  Cells 
were washed with PBS thrice and incubated for 1 h at 37°C in cell lysis buffer.  
An aliquot of the solubilized cells was used to determine total protein 
concentration (BioRad) and another aliquot was used to count the total 
radioactivity in the cells by scintillation counting.  Relative proteolysis was 
determined by calculating TCA soluble radioactivity in the medium relative to total 
radioactivity present in the well.  Relative proteolysis was normalized to protein 
concentration from the solubilized cells. 
3.3.6  Western blot analysis 
Cells were harvested, washed with PBS, lysed in RIPA buffer containing 
Complete Protease Inhibitor Cocktail (Roche Diagnostics) and 0.1% β-
mercaptoethanol, and sonicated.  Liver, cerebellar and telencephalon samples 
were homogenized with the same buffer using a motor homogenizer.  Lysates 
were precleared by centrifugation at 15,000g for 10 min at 4°C.  For analysis of 
p62 levels in the pellet, protein concentrations were determined for crude lysates 
and sample concentrations normalized.  Samples were centrifuged at 15, 000g 
for 10 min at 4°C and pellets were resuspended in 1x loading buffer.  All samples 
were electrophoresed through either 10% SDS-polyacrylamide gels or 4-20% 
Tris-glycine gradient gels (Cambrex) and then transferred to nitrocellulose 




proteins were detected by chemiluminescence (PerkinElmer).  Western blots 
depicted show representative results from one of three experiments unless 
otherwise stated. 
3.3.7  Footprint analysis 
Animals were trained to walk across an 83 cm long platform (7 cm wide) until the 
mice were able to consistently walk down the center of the path.  Forepaws and 
hindpaws were painted maize and blue, respectively, with nontoxic paint and 
animals walked over white paper.  Images represent at least two mice per 
genotype. 
3.3.8  Functional proteasome assay 
Proteasome activity in mouse liver lysates was determined using the 20S 
Proteasome Assay Kit, SDS-Activation Format (K-900) from Boston Biochem.  
Previously frozen liver samples were homogenized in sample buffer (2.5 mM 
Tris-HCl, pH 7.5/0.1 mM EDTA, pH 8.0/0.1 mM NaN3) and supernatants were 
collected after spinning at 15,000g for 30 minutes at 4°C.  100 µg of soluble 
protein was added to a 96 well plate and brought to a final volume of 60 µl with 
sample buffer.  SDS-activation buffer was added to all samples and allowed to 
equilibrate for 5 minutes at room temperature.  Substrate solution (Suc-LLVY-
AMC) was then added and fluorescent AMC counts released every 5 minutes for 
1 hour at 37°C (excitation wavelength 390, emission filter 510) were measured 
by an Ascent Fluroskan microplate reader.  Each sample had a companion well 




proteasome inhibitor) for 10 minutes at room temperature to block the 
proteasome and control for non-specific degradation of the substrate.  Data 
represent the rate of AMC release per minute in samples subtracted from 
companion MG132-treated wells. 
3.4  Results 
3.4.1  NPC1/tau double null mutant mice demonstrate an exacerbated 
phenotype 
To determine the extent to which tau loss-of-function affects the NPC 
phenotype in vivo, we generated NPC1/tau double null mutant mice (Npc1 -/-; 
Mapt -/-).  The first indication of a genetic interaction between Mapt and Npc1 
came from breedings to generate these mice, when we noted the occurrence of 
significantly smaller litters when both parental genotypes were Npc1 +/-; Mapt -/-.  
While Npc1 heterozygotes deficient in tau generated litters that averaged ~4 
pups, the presence of one or two functional tau alleles in both parents resulted in 
significantly larger litters (Fig. 1A).  This affect was not solely attributable to Mapt 
deficiency, as Npc1 +/+; Mapt -/- mice generated litters that averaged ~8 pups, 
similar to wild type (Fig 1C).  We considered the possibility that smaller litters 
generated by Npc1 +/-; Mapt -/- mice reflected a selective loss of double null 
mutant pups.  However, analysis of the Npc1 null allele frequency distribution in 
pups from Npc1 +/-; Mapt -/- breedings showed that there was no significant 
decrease in the number of Npc1 -/- pups generated when compared with litters 




results indicate that small litter size was not due to the specific loss of NPC1/tau 
double null mutants, but rather suggest that it was attributable to other affects on 
fertility or fetal survival.  
 
Figure 3.1  Mapt deletion decreases litter size of NPC1-deficient mice.  
(A)  Average litter size (mean +/- SEM) generated by Npc1 +/- parents, 
stratified by parental Mapt genotype. Npc1 +/-; Mapt -/- crosses 
generated fewer pups on average (p=0.0002 by ANOVA with Newman-
Keul’s Multiple Comparison Test) than parents with at least one 
functional Mapt allele. N = number of litters.  (B)  Npc1 null allele 
distribution among generated pups, stratified by parental Mapt 
genotype.  No significant deficit of Npc1 -/-; Mapt -/- mice was observed 
when data were analyzed by Chi-squared analysis (p=0.1924).  N = 
number of mice.  (C)  Litter size (mean +/- SEM) of wild type (black bar) 
and Mapt -/- (white bar) mice.  N = number of litters; n. s. = not 





The double null mutant mice that were successfully generated displayed a 
markedly more severe phenotype than NPC1 single null mutants.  Young female 
NPC1 null mutants that were haploinsufficient or deficient in tau weighed 
significantly less than NPC1 single null mutants (Fig 3.2, A, left panel).  
Additionally, both male and female double null mutants died earlier than NPC1 
single null mutants, which succumb to disease between 8 - 12 weeks in our 
colony.  In contrast, approximately half of the NPC1/tau double null animals died 
by 5 weeks (Fig. 3.2, B and C).  Mice haploinsufficient for Mapt (Npc1 -/-; Mapt 
+/-) also demonstrated this robust shift in the survival curve, establishing that 
even partial loss of tau expression was detrimental to the survival of NPC mice.  
Interestingly, this exacerbation of the weight and death phenotypes associated 
with NPC1 deficiency occurred in the complete absence of tau, excluding tau 
hyperphosphorylation or PHF formation as a disease mechanism.  
 While the severity of the phenotype exhibited by double null mutants 
varied, many of the animals (approximately half) exhibited mild facial dysmorphia 
(shortened snout), kyphosis (Fig. 3.3, A) and an abnormal tip toe walking gait 
(Fig. 3.3, B and C), which has never been documented in NPC1 single null 
mutants.  Footprint analysis clearly showed the tip toe walking phenotype due to 
the inability of double null mutants to press their paw pads down on the paper 
(Fig. 3.3, C).  Additionally, almost all of the double null mutant males that 
survived to at least 5 weeks developed penile prolapsed (Fig. 3.3, D).  This 
constellation of features establishes that tau deletion exacerbates the systemic 




Figure 3.2  Decreased weight and early death of NPC1/tau double null 
mutant mice. 
(A)  Weight (mean +/- SEM) of 5 week old female (left panel) and male (right 
panel) mice.  A significant difference between single (Npc1 -/-; Mapt +/+) 
and double (Npc1 -/-; Mapt -/-) null mutant mice was observed only in 
females, while all Npc1 -/- males demonstrated decreased weights when 
compared to controls.  *, ** and *** signify p-values of <0.05, <0.01 and 
<0.001, respectively, by ANOVA with Newman-Keul’s Multiple Comparison 
Test.  (B)  Survival curve.  Npc1 -/-; Mapt +/- (green line) and Npc1 -/-; Mapt -
/- (blue line) are significantly different (p<0.0001 by Log-rank test) than WT, 
Mapt null (black line) and Npc1 -/-; Mapt +/+ (red line) mice.  (C)  Age of 
death for Npc1 -/-; Mapt +/+ (red triangles), Npc1 -/-; Mapt +/- (blue squares) 







3.4.2  Tau knock-down impairs autophagy in NPC1 deficient cells 
We next sought to establish the mechanism by which tau deletion 
exacerbates the NPC phenotype.  Since tau is a microtubule binding protein 
implicated in the regulation of intracellular trafficking, we hypothesized that 
impairments of critical microtubule-dependent processes might underlie the 
worsened phenotype of double null mutants.  Our prior work established that 
NPC1 deficiency increases basal autophagy (25), and others have shown that 
transport along microtubules is required for autophagic protein degradation (26, 
27).  We therefore examined whether tau deletion affects autophagy in NPC1 
deficient mice and cells. 
To monitor the autophagic pathway, we used the microtubule-associated 
protein 1 light chain 3 (LC3) (30, 31).  This protein is modified from its LC3-I 
cytosolic form to a more rapidly migrating, lipidated LC3-II form associated with 
autophagosome formation and the induction of autophagy.  
Immunohistochemical analysis of liver from 10-week old mice demonstrated an 
increased accumulation of LC3-positive vacuoles in NPC1/tau double null 
mutants compared to NPC1 single null mutants (Fig.3.4, A).  A similar 
accumulation of LC3-positive vacuoles has been associated with impaired 
autophagic flux in several in vitro model systems (32, 33) and in some lysosomal 




Figure 3.3  Systemic phenotypes associated with NPC1/tau double null 
mutant mice 
(A)  Double null mutant mice (Npc1 -/-, Mapt -/-) demonstrate shortened 
snout and kyphosis when compared to control mice (Npc1 +/+, Mapt -/-).  
(B)  Still images of video reveal abnormal gait of double null mutant mice 
(Npc1 -/-, Mapt -/-, bottom panel).  (C)  Footprint analysis demonstrates tip 
toe walking gait of 4 week old double null mutant mice (Npc1 -/-, Mapt -/-) 
when compared to single null (Npc1 -/-, Mapt +/+) and control mice (Npc1 
+/+, Mapt -/-) of the same age and sex.  (D)  Nearly all double null mutant 
males that survive past 5 weeks of age demonstrate penile prolapse, while 
NPC1 single null males and WT males rarely exhibit this phenotype 
(p=0.038 by ANOVA) 
 
These results prompted us to examine levels of LC3-II and p62 in tissue 
lysates from NPC1/tau double null mutants.  LC3-II is a robust marker of 
autophagy induction and p62 is a marker of autophagic flux.  p62 links 
ubiquitinated proteins to LC3, and is itself incorporated into autophagosomes and 




autophagic pathway can lead to the accumulation of insoluble p62.  Western blot 
analyses demonstrated increased soluble LC3-II in liver (Fig. 3.4, B) and brain 
(Fig. 3.5, A – C), and increased SDS-insoluble p62 in brain (Fig. 5A – C) of 
NPC1 deficient mice.  These findings demonstrate that NPC1 deficiency in vivo 
leads to the robust induction of autophagy coupled with impaired autophagic flux, 
a situation that may lead to autophagic stress and predispose to autophagic cell 
death (37).  Alterations in LC3-II and p62 expression were also observed in 
tissue lysates from NPC1 single null mutants as young as 4 weeks (data not 





 Figure 3.4  Reduction of tau impairs autophagy in NPC1 deficiency. 
(A)  Immunohistochemical staining for LC3 demonstrates frequent LC3-
positive vacuoles in liver of 10 week old double null mutant (Npc1 -/-; Mapt 
-/-) when compared to single null mutant  (Npc1 -/-; Mapt +/+) or wild type 
mice.  (Original magnification, 1000 x.)  (B)  Liver lysates from 10 week old 
mice were probed by western blot for expression of LC3.  Both double null 
(Npc1 -/-, Mapt -/-) and single null mutant mice (Npc1 -/-, Mapt +/+) 
demonstrate increased levels of LC3-II compared to controls.  (C)  Relative 
MAPT mRNA levels (mean +/- SEM) 72 hours post treatment with non-
targeted (black bars) or MAPT siRNAs (white bars), as determined by 
TaqMan assay. Targeted siRNAs significantly reduced endogenous MAPT 
mRNA expression in control (p=0.008 by Student’s unpaired t-test) and 
NPC1-deficient (p=0.002) cells.  (D)  Human fibroblast lysates from control 
(lanes 1 and 2) and NPC1-deficient (lanes 3 and 4) cells were analyzed by 
western blot for expression of LC3 (top) and GAPDH (bottom) 72 hours 
post treatment with non-targeted (lanes 1 and 3) or MAPT siRNAs (lanes 2 
and 4).  (E)  Degradation of long-lived proteins in control (left panel) and 
NPC1-deficient human fibroblasts (right panel) following transfection with 
non-targeted (black bars) or MAPT siRNAs (white bars).  Data (mean +/- 
SEM) are reported relative to non-targeted siRNA-transfected cells at 72 
hours.  Relative proteolysis is significantly decreased in NPC1-deficient 






While in vivo deletion of tau in NPC mice led to subtle changes in 
autophagic markers manifest by the accumulation of LC3-positive vacuoles in the 
liver, the acute down-regulation to tau expression in vitro markedly reduced both 
autophagic induction and flux in NPC1 deficient cells.  To reduce MAPT 
expression, we used pooled, targeted siRNAs to specifically knockdown MAPT in 
control (Fig. 3.4, C, left panel) and NPC1-deficient primary human fibroblasts 
(Fig. 4C, right panel).  These cells were selected for analysis since prior studies 
have established that they express all human tau isoforms (38).  Treatment with 
MAPT siRNAs significantly decreased endogenous MAPT mRNA levels.   
Reduction of tau in NPC1-deficient but not control cells reduced the amount of 
LC3-II (Fig. 3.4, D), signifying an overall reduction in the amount of 
autophagosomes present.  These results demonstrate that an acute reduction of 






Figure 3.5  Increased LC3-II and p62 in brains of NPC1-deficient mice. 
(A-C)  Lysates from the telencephalon (A) and cerebellum (B, C) of NPC1 
single null and NPC1/tau double null mutant mice demonstrate increased 
levels of LC3-II and pelleted p62 compared with controls. 
 
To independently confirm these results, we sought to determine if MAPT 
knock-down decreased flux through the autophagic pathway by measuring the 
degradation of long-lived proteins (39).  This assay provides a quantitative 
measure of flux through autophagy and provides a functional readout of this 
pathway (40, 41).  Control and NPC1-deficient cells were treated with MAPT or 
non-targeted siRNAs, and then labeled for 48 hours with 3H-leucine.  The cells 
were washed, re-fed and trichloroacetic acid soluble radioactive counts released 
into the media were measured 24 hours after labeling.  NPC1-deficient 
fibroblasts treated with MAPT siRNAs demonstrated significantly lower levels of 
long-lived protein degradation than cells treated with non-targeted siRNAs (Fig. 
3.4, E, right panel). In contrast, long-lived protein degradation was unchanged in 




conclude that an acute reduction of MAPT expression in NPC1-deficient cells is 
sufficient to inhibit the autophagic pathway.   
 
Figure 3.6  The ubiquitin-proteasome pathway remains intact in NPC1 
deficient animals. 
(A)  Activity of 20S proteasome assayed in liver lysates of 10 week old mice 
(mean +/- SEM).  p>0.05 by ANOVA.  (B)  Western blot analyses of liver 
lysates from 10 week old mice demonstrate equal levels of expression for 
hsp40, stress-inducible hsp70, hsp90 and 20S proteasome subunits. 
 
Trafficking along microtubules is needed for efficient protein quality 
control, processes that in addition to autophagy depend on protein degradation 
by the ubiquitin-proteasome pathway (42).  To determine whether tau deletion 
also affected this pathway, we evaluated proteasome function in NPC1 single 




a source of active 20S proteasomes.  Cleavage of Suc-LLVY-AMC, a substrate 
for the chymotrypsin-like activity of the proteasome, was unchanged by Npc1 and 
Mapt genotype (Fig. 3.6, A).  Similarly, expression of 20S proteasome subuints 
was unchanged in single and double null mutant mice compared with wild type 
controls (Fig. 3.6, B).  Additionally, no induction of heat shock proteins indicative 
of a stress response was detected in single or double null mutants (Fig 3.6, B).  
These data indicate that the function of the ubiquitin-proteasome pathway is 
intact in NPC1/tau double null mutant mice, and indicate that tau deletion 
primarily impairs protein degradation through autophagy in NPC1 deficiency.  
3.5  Discussion 
The tauopathies are a large and diverse collection of neurodegenerative 
disorders that have in common the accumulation of hyperphosphorylated and 
aggregated tau species (45).  This group of diseases includes forms of 
frontotemporal lobar dementia caused by MAPT mutations, establishing a role for 
tau pathology in human disease (46, 47).  However, most tauopathies, including 
NPC, lack these mutations, and the contribution of tau to the pathogenesis of 
these disorders has remained poorly defined.  Using NPC as an example of this 
latter group of disorders, here we show that tau deletion exacerbates the disease 
phenotype in vivo.  Through the generation of NPC1/tau double null mutants, we 
establish that tau deficiency decreases litter size and survival, and worsens the 
systemic phenotype of NPC1 null mutants.  Our findings indicate that diminishing 
functional tau has dire consequences in the setting of certain neurodegenerative 




distinct from toxicity mediated by tau protein aggregation, a mechanism that has 
attracted widespread attention.  In contrast to the results reported here, a recent 
study demonstrated that reduction of endogenous tau partially ameliorates the 
phenotype of Alzheimer disease mice (48).  This suggests that both tau loss-of-
function and toxic gain-of-function mechanisms modulate disease progression in 
tauopathies, implying the existence of two distinct classes within this large and 
diverse group of neurodegenerative disorders.  Furthermore, we suggest that 
alterations in tau mediated by hyperphosphorylation may similarly act through a 
loss-of-function mechanism to exacerbate the phenotype of NPC patients. 
We observed that tau deletion causes an accumulation of autophagic 
vacuoles in the liver of NPC mice, and that knockdown of MAPT expression 
decreases autophagic induction and flux in NPC1-deficient fibroblasts.  These 
results indicate that tau contributes to the regulation of autophagy in NPC1 
deficiency, and that loss of functional tau impairs this pathway.  Our findings build 
on published data showing that NPC1 deficiency robustly increases basal 
autophagy (24-26) and stimulates flux through the autophagic pathway in a 
Beclin-1 dependent manner (26).  As diagrammed in Figure 7, we propose that 
this induction of basal autophagy acts as a pro-survival response to facilitate 
recycling of critically needed cellular components in NPC1 deficient cells.  Tau 
deletion diminishes this response, perhaps through affects on microtubule based 
trafficking.  The resulting exacerbation of systemic pathology suggests that tau-
dependent processes normally buffer the severity of the NPC phenotype.  Our 




NPC1 deficient cells, and suggest that other disorders where autophagy 
contributes to pathogenesis may be similarly sensitive to affects of tau deletion. 
Our findings suggest the intriguing conclusion that tau loss-of-function 
may be more deleterious to the progression of NPC pathology than the 
accumulation of hyperphosphorylated tau species.  This novel mechanism for 
modulating the severity of the disease phenotype indicate that new treatment 
approaches aimed at restoring normal tau function could ameliorate or delay 
NPC disease progression.  Other tauopathies may be similarly affected by tau 
loss-of-function, suggesting that this approach could prove beneficial in multiple 
disorders characterized by tau abnormalities.  Additionally, our data raise the 
possibility that allelic differences in tau expression levels may modify the NPC 
phenotype.  Indeed, it is well established that patients with the same mutation in 
NPC1 can have divergent clinical presentations, suggesting the existence of 
genetic modifiers (49, 50).  The work presented here identifies MAPT as a 
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Chapter 4  
Generation of a Conditional Mouse Model of Niemann Pick 
Type C Disease 
 
4.1  Abstract 
 Niemann-Pick C Disease is a recessive sphingolipid storage disorder 
characterized by global progressive neurodegeneration for which there is no cure 
or effective treatment.  About 95% of cases are caused by loss of function 
mutations in the Npc1 gene.  It is currently unknown which cell types within the 
central nervous system are causally involved in disease pathogenesis and 
whether these effects occur at a specific time in development.  To address these 
questions, we generated a conditional null mutant of the mouse Npc1 gene.  A 
9.3 kb fragment of Npc1 genomic sequence was isolated from a C57BL/6 BAC 
library, and used to generate a 3.0 kb 5’ arm and a 5.2 kb 3’ arm of a targeting 
construct.  These arms were cloned into pFlox-Flp-Neo, a vector containing the 
neomycin resistance gene and the PGK promoter flanked by two FRT sites.  
Npc1 exon 9 and flanking intronic sequence were amplified by high fidelity PCR, 




functionally test the loxP and FRT sites, we utilized arabinose inducible Cre and 




induction confirmed appropriate Cre- and Flp-mediated recombination.  The 
construct was then electroporated into Bruce4 embryonic stem (ES) cells, a line 
derived from C57BL/6J mice.  Approximately 900 neomycin resistant clones were 
selected and screened by Southern blot for appropriate integration.  Correctly 
targeted clones that contained 40 chromosomes were injected into albino 
C57BL/6J blastocysts to generate ES cell-mouse chimeras.  Two male chimeras, 
which were generated from two independent ES cell clones, were bred with 
albino C57BL/6 females (B6-tyrc-2J).  These breedings yielded multiple mice 
which harbor loxP flanked exon 9 of the Npc1 allele.  Studies utilizing these mice 
are expected to provide insights into the progression and mechanism of this 
devastating neurodegenerative disorder. 
4.2  Introduction 
The progressive and disabling neurodegeneration that occurs in patients 
with Niemann-Pick C has been studied in several animal models.  The best 
characterized and most commonly used are mice in which an insertional 
mutation into exon 9 of the Npc1 gene causes a frame shift and truncation of the 
encoded protein (npc1 -/- mice) (1).  In these mice, as in patients with the 
disease (2-5), neurons accumulate lipids including glucosylceramide, 
lactosylceramide, complex gangliosides and cholesterol (6-8), abnormally 
swollen axons are frequent, and decreased myelination is present in the cerebral 
white matter (9).  These histological changes are associated with behavioral 
deficits, including impaired gait and rotarod performance, and early death.  This 




expression in the nervous system.  In support of this conclusion are studies in 
mice demonstrating that prion-promoter driven transgenic over-expression of 
NPC1 primarily in the brain of npc1 -/- mice prevents neurodegeneration in the 
face of moderate continued visceral pathology (1).  However, it remains poorly 
understood how loss of functional NPC1 results in such marked disease.  
NPC1 is widely expressed in the central nervous system by neurons, 
oligodendrocytes and astrocytes, all which accumulate lipids in this disorder (10, 
11) and traffic cholesterol abnormally in npc1 -/- mice (12-14).  Recent studies 
have demonstrated that NPC1 deficiency leads to cell autonomous neuronal 
death in chimeric mice that express functional protein in only some cells (15). 
While these data provide important information on the mechanism of toxicity, it 
remains uncertain whether dysfunction or death of cells other than neurons also 
contributes to the Niemann-Pick C disease phenotype.  For example, 
oligodendrocytes, which normally form the lipid rich myelin sheath, do not 
appropriately myelinate axons in npc1 -/- mice (9) and may thereby contribute to 
neuronal pathology.  This effect may be mediated in part by disordered trafficking 
of glycosphingolipids, components of the myelin sheath that are critical for its 
interaction with axons (16).  Similarly, dysfunction of astrocytes, which enable 
normal brain development and repair through the production and transport of 
cholesterol (17, 18), has been implicated in disease pathogenesis.  Astrocyte-
derived cholesterol may impact neuronal function by promoting synaptogenesis 
(19) and by stimulating axon growth (20) .  Additionally, inflammatory mediators 




Niemann-Pick C disease, and are known to participate in neurodegeneration in 
Sandhoff disease (21, 22), another lysosomal storage disease.  These data 
indicate that loss of functional NPC1 in cells other than neurons may significantly 
contribute to disease pathogenesis, although proof of such involvement is 
currently lacking.  For these reasons and more, the generation of conditional 
Npc1 null mice will be an important resource for understanding the mechanisms 
underlying neurodegeneration seen in this devastating disorder.   
4.3  Materials and Methods 
4.3.1  Materials 
We acquired a pFlip-Flox-Neo vector from the Transgenic Animal Model Core at 
the University of Michigan.  The vector was a kind gift from Dr. James Shayman 
(23).   The Npc1 genomic BAC clone, RPCI23-37J18, was acquired from 
BACPAC Resources at Children’s Hospital Oakland Research Institute (CHORI).  
The pcDNA3 construct was purchased from Invitrogen. We obtained the Bruce4 
embryonic stem cell line from the Transgenic Animal Model Core at the 
University of Michigan.  The line was provided to the core by Dr. Colin Stewart 
and has been previously characterized (25). 
4.3.2  Deletion of FRT and loxP flanked sequence in vivo 
The arabinose inducible FLP and Cre recombinase E. coli strains, E250 and 
EL350 respectively, were a kind gift of Dr. Elizabeth Engle and were used as 




targeting construct, and transformed clones were selected for on LB-Amp plates.  
Individual clones were grown to log phase in LB-Amp media.  Diluted cultures 
were induced to express either FLP or Cre recombinase in LB-Amp with 0.1% 
arabinose for 2 hours.  The cells were plated and plasmids from individual clones 
were analyzed for the deletion of FRT or loxP flanked sequence by restriction 
enzyme digestion. 
4.3.3  Identification of embryonic stem cells with the targeted Npc1 allele 
Genomic DNA from ES cell clones was digested with EcoRV and analyzed by 
Southern blot.  5’ and 3’ probes were generated by PCR amplification of the 
Npc1 genomic BAC clone.  These probes contained sequence for exon 5 (5’-
AGTTGTTATCTTTCCTGCTTTGAGTC-3’, 5’-
ACATGTCTGACTTTTCTCTCTGAATTT-3’) and exon 18 (5’-
TCTTTAATCTTCTTTTCAGGATTCGTA-3’, 5’-
GAACTAGTCTAACCCTAACACTCAGGA-3’), respectively, both of which fall 
outside the targeting vector. 
4.4  Results 
4.4.1  Generation of Npc1 targeting construct 
 We have targeted the Npc1 gene in Bruce 4 embryonic stem (ES) cells 
derived from C57BL/6 mice.  This strategy will enable us to more rapidly 
generate mice carrying the floxed allele on a uniform genetic background without 




authored by the Transgenic Animal Model Core at the University of Michigan 
supports the use of this strategy, and suggests that C57BL/6-derived ES cells 
offer additional advantages including an increased frequency of germ line 
transmission (26).   
We chose to flank exon 9 of the Npc1 gene with loxP sites.  Deletion of 
this exon is expected to result in a frame shift mutation and truncation of the 
encoded protein, similar to that caused by an insertional mutation into exon 9 
present in the constitutive Npc1 null mutant (1).  A BAC containing the C57BL/6J 
Npc1 genomic clone was identified by a database search and digested with 
BamH1 to obtain a 9.3 kb fragment of the Npc1 gene that includes exon 9.  This 
fragment was subcloned into pcDNA3, and then digested with Ssp1 and EcoRV 
to generate a 3.0 kb 5’ arm, and with Asp718 to generate a 5.2 kb 3’ arm of a 
targeting construct.  These arms were cloned into pFlox-Flp-Neo, a vector that 
contains the neomycin resistance gene and the PGK promoter flanked by FRT 
sites.  Included within the neomycin resistance gene is an EcoRV site that was 
used during screening for recombinants by Southern blot.  Npc1 exon 9 and 
flanking intronic sequence were amplified from C57BL/6J genomic DNA by high 
fidelity PCR.  During amplification, a two base pair substitution of intronic 
sequence was made that introduced an EcoRV site 3’ to exon 9.  This site will be 
used during Southern blot analyses to identify deletion of exon 9 by Cre 
recombinase in vivo.  Both strands of the entire PCR product were sequenced, 
and then the fragment was inserted between loxP sites to allow for Cre mediated 




confirmed the accuracy of the completed targeting construct.  Schematic 
representations of the targeting construct, its relationship to genomic sequence,  
 
Figure 4.1  Strategy for generation of a conditional null mutation of the 
mouse Npc1 gene 
(a)  Endogenous Npc1 allele.  Exons are represented by numbered boxes.  
Shown are 5’ and 3’ probes containing exons 5 and 18, respectively.  (b)  
Schematic representation of targeting construct.  FRT sites are shown as 
green circles and loxP sites as yellow diamonds.  RV indicates EcoRV 
sites.  (c)  Predicted structure of allele after homologous recombination.  
(d)  Representation of targeted allele following Flp– and (e) Cre–mediated 
excision events. 
and the targeting construct, its relationship to genomic sequence, and the 
expected results of Cre and Flp mediated recombination are shown in Figure 4.1.  
 Upon completion of the targeting construct, we confirmed that the loxP 
and FRT sites flanking exon 9 and the neomycin resistance cassette were 





Figure 4.2.  LoxP and FRT sites are functional 
The completed targeting construct was transformed into E. coli that 
express arabinose inducible Flp (on left) or Cre (on right) recombinase.  
Following arabinose induction, individual colonies isolated from ampicillin-
containing plates were used as a source of plasmid DNA for restriction 
enzyme digestion.  Three individual clones from each induction were 
compared with plasmid isolated from uninduced bacteria (U). The non-
recombined plasmid contained HindIII sites (H) between the loxP and FRT 
sites, and yielded a 1.4 kb fragment after digestion.  Flp or Cre mediated 
recombination deleted one of these sites, resulting in the loss of the 1.4 kb 
band and the generation of a plasmid that was linearized by HindIII.  M 
indicates 1 kb marker. 
arabinose inducible Cre or Flp recombinase (24).  In vivo recombination was 
confirmed in several independent bacterial colonies by digestion with HindIII (Fig. 
4.2).  These data and the sequence analysis established that we have generated 




4.4.2  Embryonic stem cells with the targeted Npc1 allele 
 The targeting construct was electroporated into Bruce4 embryonic stem 
(ES) cells, a line derived from C57BL/6 mice. Approximately 900 neomycin 
resistant clones were selected and screened by Southern blot for appropriate 
integration.  Multiple correctly targeted clones were identified (Fig. 4.3), and three 
euploid clones were selected for further use.  The identification of correctly 
targeted clones indicates that our vector is able to recombine with the mouse 
Npc1 gene to generate a mutant allele.  
4.4.3  Generation of ES cell–mouse chimeras 
 The Transgenic Animal Core at the University of Michigan injected these 
targeted clones into albino C57BL/6J blastocysts to generate ES cell-mouse 
chimeras.  Two male chimeras generated from injection of independently 
targeted ES cell clones were mated with albino C57BL/6 females (B6-tyrc-2J), and 





Figure 4.3  Southern blot confirms homologous recombination in ES cells 
Genomic DNA isolated from ES cell clones was digested with EcoRV and 
analyzed by Southern blot using probes that fall outside the targeting 
construct.  The 5’ exon 5 (on left) and 3’ exon 18 (on right) probes both 
generate a 19.2 kb band from the non-recombined allele.  The recombined 
Npc1 allele generates a 5.2 kb band with the 5’ probe and a 14 kb band with 
the 3’ probe.  Shown is an example of a Southern blot from two recombined 
clones. 
across the loxP site 3’ to exon 9 and by Southern blot.  Both male chimeras sired 
multiple offspring with black fur, approximately half of which carried the floxed 
Npc1 allele (Figure 4.4). These data demonstrate that we have established two 
lines of mice, derived from independently targeted ES cell clones, which carry the 






Figure 4.4.  Germ line transmission of the targeted Npc1 allele 
(a)  Genomic Southern blot of tail biopsy derived DNA of black pups from 
two independent mouse lines after digestion with EcoRV.  5’ exon 5 (on 
left) and 3’ exon 18 probes (on right) were used, as described in Figure 3.  
(b)  PCR amplification across exon 9 and flanking intronic sequence that 
includes the 3’ loxP site generates a 946 bp band from wild type (WT) 
alleles.  Incorporation of a loxP site 3’ to exon 9 generates a 10754bp 
product that can be distinguished on argarose gel.  This larger product was 
detected when either the targeting construct (TC) or tail DNA from a mouse 
with the targeted allele (recombined) was used as template DNA. Arrows 
indicate primers used for PCR amplification. 
 
4.5  Discussion 
Our data establish that we have generated two independently derived 
lines of mice that carry the targeted Npc1 allele in which exon 9 is flanked by 
loxP sites.   We expect that this resource will significantly impact our 




one cell type were shown to play a dominant role in the development of 
neuropathology.  Such information could lead to therapeutic strategies targeted 
to a specific cell type.  One example is the potential role of inflammatory 
mediators released by activated microglia, a target that may be responsive to 
existing anti-inflammatory drugs.   
It is also unclear whether the neuropathology of Niemann-Pick C disease 
is predominantly developmental or degenerative in origin.  Conditional Npc1 null 
mice are an ideal system for resolving this question.  Recent data suggest that 
loss of functional NPC1 exerts an effect in late development that significantly 
contributes to neuropathology.  Evidence in support of this hypothesis comes 
from the observation that npc1 -/- mice treated with a single dose of 
allopregnanolone at postnatal day seven exhibit decreased storage of cholesterol 
and gangliosides in neurons, reduced Purkinje cell loss, and prolonged survival 
(27).  This observation led to the notion that NPC1 deficient cells are 
simultaneously burdened by cholesterol and ganglioside storage in late 
endosomes, yet also exhibit functional evidence of cholesterol deficiency.  This 
paucity of cholesterol in critical subcellular compartments causes an inability of 
the cell to generate cholesterol-derived mediators which influence neuronal 
survival and differentiation.  Data also demonstrate that continued weekly 
treatment with allopregnanolone enhances this survival effect (28), indicating that 
cholesterol deficiency contributes to the Niemann-Pick C disease phenotype 
beyond the first postnatal week.  To determine the extent to which NPC1 




floxed Npc1 exon 9 mice could be crossed with animals that globally express 
tamoxifen-inducible Cre recombinase.  Inactivation of the floxed Npc1 allele at 
different ages may identify a critical window for disease development and 
therapeutic intervention.  Furthermore, gene inactivation in the mature nervous 
system may lead to a slowly progressive disorder that is similar to the late-onset 
cases of Niemann-Pick C disease, for which there are no current animal models.  
 To resolve these critical and complicated issues in the study of Niemann-
Pick C disease neuropathology, we have generated a conditional null mutant of 
the mouse Npc1 gene.  This mouse model will enable studies to define the role 
of individual cell types in disease pathogenesis and to determine the effects of 
NPC1 deficiency during development and in the mature nervous system.  As 
such, this model will be an important resource to the neuroscience community 
and hopefully aid in the creation of an effective therapy for this devastating and 
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Chapter 5  
Conclusion 
 During the first part of my doctoral research, I elaborated on a previously 
reported relationship between loss of function mutations in the Npc1 gene and 
the highly conserved pathway of autophagy.  I showed that loss of NPC1 function 
increased activation of autophagy and increased the expression of Beclin 1, a 
genetic regulator of autophagy.  My recent studies demonstrated a genetic 
interaction between Mapt and Npc1.  Simultaneous deletion of both genes 
caused a disruption in the autophagic pathway in vitro and an exacerbation of the 
Niemann-Pick type C disease (NPC) phenotype in vivo.  Finally, I generated an 
important resource – a conditional mouse model of NPC.  In these animals, exon 
9 of the Npc1 allele is floxed, enabling the gene to be functionally deleted in a 
certain cells when animals are crossed with mice expressing Cre recombinase 




5.1  NPC and autophagy 
My initial studies further characterized the relationship between autophagy 
and NPC (1).  We examined cerebellum and liver from Npc1-/- and wild type 
mice since these are two known sites of pathology in mutant animals (2).  
Western blots demonstrated elevated levels of lipidated LC3 (LC3-II) as occurs 
during induction of autophagy (3, 4).  Similar analyses confirmed elevated levels 
of LC3-II in primary fibroblasts from patients with NPC as compared to age and 
sex matched controls.  Increased levels of basal autophagy in NPC1 deficient 
fibroblasts were confirmed by enhanced staining with monodansylcadaverine, by 
demonstrating frequent autophagosomes and autolysosomes by transmission 
electron microscopy, and by measuring significantly increased degradation of 
long-lived proteins.  That these differences were due to NPC1 deficiency was 
confirmed by stable expression of NPC1 protein in mutant fibroblasts, a 
manipulation that decreased basal LC3-II levels (1).  These results confirmed 
earlier observations of increased autophagy in Npc1 -/- mice (5) and were the 
first demonstration of increased autophagy in human samples.  By demonstrating 
the activation of this pathway in both humans and mice, we opened the door to 
additional studies that will define the role of autophagy in NPC pathogenesis and 
will establish the extent to which this pathway is a therapeutic target.  
Autophagy is controlled by the Akt – mTOR – p70 S6K signaling pathway 
and by Beclin-1, a crucial regulator of autophagosome formation which forms a 
protein complex with the Class III PI3K (6, 7).  To determine which of these was 




NPC1 deficient fibroblasts and mice.  Surprisingly, we found no evidence that 
enhanced basal autophagy was due to signaling through the mTOR pathway.  In 
contrast, NPC1 deficient cells and mice both showed a small, but consistent 
increase in the expression of Beclin-1 protein (1).  To determine the extent to 
which Beclin-1 contributed to increased basal autophagy, we used siRNA to 
decrease Beclin-1 expression.  Knockdown of Beclin-1 in NPC1 deficient 
fibroblasts was sufficient to reduce the basal rate of long-lived protein 
degradation by ~20%, while knockdown of Beclin-1 in control fibroblasts had no 
significant effect.  Taken together, these results indicated that enhanced levels of 
basal autophagy were mediated by increased Beclin-1 expression.  Similar 
Beclin-1 dependent, mTOR independent activation of autophagy has been 
observed in models of another neurodegenerative disorder, Huntington disease 
(8).  Subsequent to our report, it was demonstrated that Beclin-1 expression is 
decreased in Alzheimer disease brains (9), suggesting that the regulation of 
autophagy through a Beclin-1 dependent pathway is common to a diverse group 
of neurodegenerative disorders.  
A critical, unanswered question is whether activation of this pathway in 
NPC is detrimental and promotes cell death, or is compensatory and promotes 
cell survival.  To resolve this issue, autophagy will need to be modulated in NPC 
model systems and the effects on disease phenotype established.  To determine 
if increasing autophagy is beneficial to the progression of NPC, our lab has 
begun studies to administer autophagy activating compounds like rapamycin to 




Npc1 deficient mice will enable us to determine the extent to which induction of 
autophagy in vivo will ameliorate or enhance the phenotype in these animals.  If 
the induction of autophagy delays the onset of NPC, these studies could suggest 
a possible therapeutic option as rapamycin has already passed the initial stages 
of human clinical trials.   Conversely, to determine whether autophagy is 
deleterious to NPC, inhibition of this pathway by genetic mutations or small 
molecules will prove useful.  A search for compounds that specifically modulate 
the activity of the autophagic pathway in the CNS will likely yield important 
reagents for investigational studies of disease mechanisms, and may provide 
lead compounds for the development of new treatments.   
There are a variety of different endosomal sorting pathways within cells, 
and there is a distinct possibility that many of these are perturbed in NPC.  In 
addition to autophagy, another interesting candidate pathway has emerged as 
interacting with autophagy and the endosomal/lysosmal system (10, 11).  
Multivesicular bodies (MVBs) are critical for the maintenance of a variety of cell 
functions, such as receptor down regulation, viral budding and the generation of 
lysosome-related organelles (12).  MVBs are compartments that enable the 
delivery of cytoplasmic and transmembrane domains of proteins to the lysosome 
for degradation, which is also the final stage of autophagy.  The rationale of 
investigating these structures comes from recent studies identifying numerous 
MVBs in a fly model of NPC (13) and a paper describing how autophagic 
clearance of aggregated proteins is dependent upon functional MVBs (11).  It is 




intersect with autophagy contributes to the pathogenesis of NPC and related 
lysosomal storage disorders. 
5.2  NPC and tau 
 Our laboratory has recently demonstrated a genetic interaction between 
the microtubule associated protein tau (encoded by the MAPT gene) and NPC1.  
In primary human fibroblasts from patients with NPC, siRNA knockdown of MAPT 
reduced the degradation of long-lived proteins, a functional assay of autophagic 
flux.  In contrast, in control fibroblasts, MAPT knock-down caused no significant 
reduction in autophagic flux.  In vitro down regulation of MAPT expression was 
also sufficient to reduce LC3-II levels in NPC1 null cells, further demonstrating 
that loss of tau function decreased induction and flux through the autophagic 
pathway.  These results are the first demonstration of a genetic interaction 
between NPC1 and MAPT.  Before these studies, most believed that the tau 
pathology associated with NPC was an epiphenomenon and not involved in the 
disease pathogenesis.  From our cell culture studies, we have established that 
loss of MAPT function modulates the critical pathway of autophagy in NPC1 
deficient cells.   
Tau is a microtubule binding protein, and as such is positioned to 
influence the efficiency of numerous intracellular trafficking events.  In addition to 
autophagy, other protein quality control pathways such as the proteasome and 
MVBs require microtubule based trafficking for efficient protein degradation (14-




neurodegeneration (8, 19-22), and it is possible that loss of tau function 
influences several of these pathways in NPC.  In order to determine the extent to 
which dysfunction of the proteasome or MVBs occurs in NPC1 null cells and is 
modulated by tau, one could knockdown MAPT in NPC1 deficient fibroblasts and 
then monitor the degradation of specific proteins.  Appropriate targets include a 
form of GFP protein targeted for degradation by the proteasome (GFPu) (23), or 
the receptor for PDGF which traffics to MVBs after ligand binding.  These 
proposed studies would determine the extent to which impairments of protein 
quality control pathways are involved in NPC pathogenesis and if genetic 
deletion of MAPT modulates them. 
Our in vivo studies conclusively showed that deletion of Mapt exacerbates 
the NPC phenotype.  While attempting to generate double null mice (Mapt -/-; 
Npc1 -/-), we noticed a significant decrease in litter size.  These small litters were 
not due to a selective loss of NPC1 null mice since the frequency distribution of 
the Npc1-null allele remained constant compared to litters generated by mice 
with normal levels of tau.  Instead, these data provided the first demonstration 
that NPC1 and tau interact in vivo to affect fertility.  Although the precise 
mechanism underlying this affect is currently unknown, it is interesting to note 
that functional autophagy is critical for early embryogenesis in mice (24).  
Of the few double null animals that were generated, these mice 
demonstrated a much more severe phenotype than single null mutants (Mapt 
+/+; Npc1 -/-).  These animals showed decreased weight by 5 weeks of age, 




double null animals also showed mild facial dysmorphia with a shortened snout, 
kyphosis and an abnormal, “tip-toe” walking gait.  These data provide the first in 
vivo evidence that Mapt loss of function exacerbates a disease phenotype.  
Previous reports in Alzheimer disease (AD) have demonstrated that loss of 
function mutations in Mapt actually ameliorate some of the disease phenotypes 
in a mouse model (25).   Our data highlight the fact that tau pathology plays 
different roles in disease pathogenesis in various tauopathies. 
Histochemical analyses of the double null mutants (Mapt -/-; Npc1 -/-) 
demonstrated numerous large autophagic vacuoles in the liver, a common site of 
pathology in NPC.  In contrast, autophagic vacuoles in the livers of single null 
mutants (Mapt +/+; Npc1 -/-) were qualitatively smaller.  Biochemical analyses 
showed a slight, but not statistically significant, increase in LC3-II levels in the 
livers of double null mutants compared to single nulls.  No change in soluble or 
pelleted p62 was observed.  These results suggest a possible blockage of the 
autophagy in double null mutants.  However, perhaps because of more subtle 
effects in vivo than in vitro, because of compensatory processes, or because our 
assays to measure autophagy in living mammals are relatively insensitive, we 
were unable to definitively establish that Mapt deletion impairs autophagy in NPC 
mice. 
Our studies have yielded compelling data demonstrating a previously 
unreported relationship between the microtubule-associated protein tau and 
Npc1.  Our data demonstrate an important role for loss of normal tau function in 




aspects of the NPC phenotype.  Our data also highlight the fact that tau 
hyperphosphorylation, which occurs similarly in NPC, AD and other tauopathies, 
can contribute to disease by triggering a loss of function and acting through 
pathways that are distinct from the formation of toxic protein aggregates. 
 Our studies demonstrate that NPC1 deficiency leads to increased levels of 
basal autophagy and that this activation is dependent upon Beclin-1.  We further 
demonstrate that reduction of functional tau causes a disruption of autophagy 
and an exacerbation of the NPC phenotype in vivo.  Our model in Figure 5.1 
demonstrates the relationship between loss of function mutations in NPC1 and 
activation of autophagy via increased expression of Beclin-1.  We hypothesize 
that this increase in basal autophagy is a protective response, and that reduced 
tau function, by either hyperphosphorylation or genetic deletion, inhibits this 
protective response.  We propose that the diminished autophagic capacity 





5.1 Proposed relationship between NPC1 deficiency, autophagy and tau 
Functional deficiency of NPC1 impairs intracellular lipid trafficking and 
leads to the accumulation of unesterified cholesterol, sphingolipids and 
complex gangliosides in the late endosomal/lysosomal network.  These 
defects stimulate a Beclin-1 dependent increase of basal autophagy, which 
we propose exerts a protective effect by facilitating the re-use of critical 
cellular components.  Deletion of endogenous tau abrogates this response 
and exacerbates the NPC phenotype.  We speculate that similar effects may 
be triggered by tau hyperphosphorylation as occurs in NPC patients. 
 
5.3  Conditional Npc1 mutant mouse 
We have successfully generated a conditional mouse model of NPC with a 
floxed exon 9 of the Npc1 allele.  We have deleted this sequence in vivo, and 




(unpublished data).  These animals will aid in determining whether a single cell 
type is primarily responsible for the pathogenesis of NPC and therefore is a 
primary therapeutic target.  There are a number of possible avenues to 
investigate with these animals, and our lab has begun to cross these mice with 
various Cre-expressing mice to elucidate the cell type specific contributions to 
NPC.    
The Purkinje cells of the cerebellum are the most sensitive to NPC1 loss 
of function and die rapidly in the mouse model of the disease.  Because of these 
attributes, Purkinje cell specific deletion of Npc1 makes for an attractive first 
cross.  We have obtained mice (Jackson Labs Tg(Pcp2-cre)1Amc/J) which 
express Cre recombinase specifically in Purkinje cells of the cerebellum by 
expressing the gene under a modified mouse Purkinje cell protein 2 (Pcp2) 
promoter.  This cross will help determine the extent to which NPC1 deficiency 
causes cell autonomous neuronal toxicity. 
  Additional interesting crosses would include two glial cell type specific 
Cre recombinase lines enabling microglia (26) and astrocyte (27) specific gene 
deletion.  Emerging evidence supports the role of these glial cells in the 
progression of NPC (28) and other neurodegenerative disorders such as AD 
(29).  Microglia are the macrophages of the brain, and inflammation has been 
implicated in many neurodegenerative disorders (30) including NPC (31).  
Deletion of Npc1 in microglia specifically will lead to a better understanding of the 
role of neuroinflammation in NPC pathogenesis.  The NPC1 protein is also highly 




Npc1 in astrocytes increased the lifespan of NPC mice (32).  Astrocytes promote 
normal brain development and repair through the production and transport of 
cholesterol (33, 34), and their dysfunction has been implicated in disease 
pathogenesis.  Astrocyte-derived cholesterol may impact neuronal function by 
promoting synaptogenesis (35) and by stimulating axonal growth (36).  These 
data suggest deletion of NPC1 expression in astrocytes could yield interesting 
results, however, cell type specific deletion of Npc1 (or any other gene) in 
astrocytes has been difficult to achieve.  The most commonly used astrocyte 
specific promoter, from the glial fibrillary acidic protein (GFAP) gene, is highly 
expressed in post-mitotic astrocytes but is also weakly expressed in neuronal 
precursor cells (37).  In order to keep Npc1 expression intact for all cells of the 
CNS besides astrocytes, a tamoxifen-inducible system could be employed to 
express Cre recombinase in this glial cell population alone (Mutant Mouse 
Resource Center B6 (C3)-Tg (GFAP-cre/Esr1)/13Kdmc).  These crosses could 
help determine the extent to which astrocytic involvement contributes to the 
neuropathology seen in NPC. 
In addition to helping define the contribution of specific cell types to 
disease pathogenesis, the new conditional mouse model could be used to 
determine whether there is a temporal component to NPC disease.  By crossing 
the conditional animal to tamoxifen inducible Cre mice (Jackson Labs B6.Cg-Tg 
(cre/Esr1)5Amc/J), the experimenter will globally delete the floxed sequence 
when tamoxifen is introduced.  These studies will allow for in vivo ablation of 




NPC is a degenerative disorder of childhood and not a disorder of fetal 
development (38), reagents to specifically test this notion have not been 
previously available.  To establish the consequences of Npc1 loss of function 
during development and in the adult nervous system, tamoxifen injections could 
be administered to animals of different ages and the consequences determined. 
 The studies proposed utilizing the conditional mouse model I generated 
will help define the roles of many different cell types in the pathogenesis of NPC, 
and will establish the extent to which a specific developmental window is critical 
for disease pathogenesis.  The answers to these questions may help determine 
treatment targets and timing, and will likely yield important insights into the 
normal function of NPC1.  The generation of this reagent has been a valuable 
experience for me as a scientist, and it is my hope that it will be a useful reagent 
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